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HIV/AIDS associated cancers are cancers whose incidences are much higher in
HIV/AIDS patients than in the general population. HIV as one of the chronic in-
fections involves chronic antigenic stimulation by persistent self-antigens or for-
eign antigens and the stimulation activates B cells and induces their uncontrollable
growth. Cancer and HIV co-existence both in vivo and in vitro in a cancer immune
environment leads to specific cytokines being produced by various immune cells
and the cancer cells. In this thesis, we develop a mathematical model describ-
ing the cancer-immune system interaction in the presence of HIV and HIV treat-
ment. In particular, we focus on the most common cancer in AIDS patients; the
non-Hodgkin’s lymphoma (NHL). The formulated model, described by non-linear
ordinary differential equations, shows existence of multiple equilibria whose sta-
bility and bifurcation analysis are presented. Our results suggest existence of a low
endemic state (non-aggressive) and a higher endemic (aggressive state). At a low
ii
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cancer state, patients can live for a longer period of time with the cancer. How-
ever, initiation of HIV treatment in patients with NHL is observed to reduce the
cancer cell density to lower endemic states and this might explain why some of the
HIV-infected patients can live with cancer for many years. Highly active antiretro-
viral therapy (HAART) used for HIV treatment is a combination therapy ("cocktail"
of drugs), that includes reverse transcriptase inhibitor (RTI) and protease inhibitor
(PI) in different proportions; it is more effective in treating HIV than a single drug
therapy. In many communities in sub-Saharan Africa, HAART is available but not
anti cancer drugs. We explore how effective the combination therapy in HIV asso-
ciated cancer is in reducing cancer growth. Our model simulations show how to
best choose the proportions of RTI and PI in order to maintain an acceptable level
of CD+4 T cells and, at the same time, reduce the growth of cancer cells as much
as possible. The results obtained also give an estimate of the efficacies of the drugs
in the HAART regimen given to people living with HIV. In addition, the results
also explain why late initiation of HIV treatment might not be helpful to cancer
patients. Furthermore, in case of chemotherapeutic intervention, our results might
explain why a few of these chemotherapeutic drugs are more effective when given
at a slow continuous rate. The models present some interesting research outcomes
on treatment of HIV related cancers that can influence their treatment and manage-
ment.
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Opsomming
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limfoom groei dinamika
(Modelling the role of HIV and its treatment in non-Hodgkin lymphoma growth dynamics )
Rosemary Akinyi Aogo
Departement Wiskundige Wetenskappe,
Universiteit van Stellenbosch,
Privaatsak X1, Matieland 7602, Suid Afrika.
Tesis: MSc. (Wiskunde)
Desember 2015
MIV/VIGS-verwante kankers is kankers wie se voorkoms in MIV/VIGS pasie¨nte
baie groter is as in die algemene bevolking. MIV, as een van die kroniese infeksies,
vereis kroniese antigeniese stimulasie deur aanhoudende self- of vreemde antigene.
Hierdie stimulasie aktiveer B-selle en gee aanleiding tot hul onbeheerbare groei.
Die saambestaan van kanker en MIV, beide in vivo en in vitro, in ‘n kanker- im-
muunomgewing lei tot die produsering van spesifieke sitokiene deur verskeie im-
muunselle en die kankerselle. In hierdie tesis ontwikkel ons ‘n wiskundige model
wat die kanker-immuunstelsel se interaksie in die teenwoordigheid van MIV en
MIV behandelings toon. Ons fokus, in die besonder, op die mees algemene kanker
in MIV pasie¨nte: nie-Hodgkin se limfoom (NHL). Die geformuleerde model, wat
nie-lineere gewone differensiaalvergelykings beskryf, toon die bestaan van vers-
keie ewewigte wie se stabiliteit en bifurkasie analise verskaf word. Ons resultate
dui daarop bestaan âA˘N´âA˘N´van ’n lae endemiese staat ( nie- aggressiewe ) en ‘n
iv
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hoe¨r endemies ( aggressiewe staat) . Op ‘n lae kanker toestand is, kan pasie¨nte leef
vir ‘n langer tydperk van die tyd met die kanker. Dit word egter waargeneem in
pasie¨nte met NHL dat die begin van MIV- behandeling hierdie lae epidemiese state
van die kankerselle verminder.
Hoogs aktiewe antiretrovirale terapie (HAART) wat gebruik word vir MIV be-
handeling is ’n kombinasie terapie (“cocktail"van geneesmiddels) wat omgekeerde
transkriptase inhibeerder (RTI) en protease-inhibeerder (PI) in verskeie proporsies
insluit; dit is meer effektief in die behandeling van MIV as ’n enkele geneesmiddel-
terapie. In baie van die gemeenskappe in sub-Saharan Afrika is HAART, eerder as
antie-kanker geneesmiddels, beskikbaar.
Ons ondersoek hoe effektief die kombinasie terapie in HIV-verwante kankers is om
kankergroei te verminder. Ons modelsimulasies toon hoe om die beste proporsie
van RTI en PI te kies om ’n aanvaarbare vlak van CD+4 selle te handhaaf, en ter
selfde tyd, die groei van kankerselle soveel as moontlik te verminder. Die resultate
toon ook ‘n beraming van die effektiwiteit van die geneesmiddels in die HAART
prosedure wat gegee word aan di`e wat MIV het. Ook verduidelik die resultate hoe-
kom die MIV behandeling nie so nuttig onder kankerpasie¨nte, wat die behadeling
laat begin, is nie. Bykomend, in die geval van chemoterapeutiese intervensie, mag
ons resultate verduidelik hoekom sommige van die chemoterapeutiese geneesmi-
delle meer effektief is wanneer dit teen ’n stadige deurlopende tempo verskaf word.
Die model toon interressante uitkomste van die navorsing oor die behandeling van
MIV-verwante kankers wat hul behandeling en bestuur kan bei¨nvloed.
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Chapter 1
Introduction
1.1 Cancers and HIV
AIDS was first described in 1981 and the first definitions included certain oppor-
tunistic infections, kaposi sarcoma and central nervous system (CNS) lymphoma.
In 1984, a multicenter study described the clinical spectrum of non-Hodgkin’s lym-
phomas in the populations at risk for AIDS [1]. Going forward, the Centers for Dis-
ease Control and Prevention (CDC) in 1985 and 1987 revised the AIDS definition
to include the human immunodeficiency virus (HIV)-infected patients who had ag-
gressive B-cell non-Hodgkin’s lymphomas (NHL) [1]. While HIV infection leads to
AIDS, complications of HIV for instance, opportunistic infections, cancers amongst
others are being experienced by people living with HIV [24].
The majority of cancers affecting HIV-positive people are Kaposi sarcoma (KS),
non-Hodgkin’s lymphoma (NHL) and invasive cervical cancer [44]. Other types
of cancer which occur somewhat more frequently in HIV/AIDS patients include
anal cancer [44], lung cancer [41, 44], and colorectal cancer [15]. KS is an indolent
cancer, involving multiple tumor of the lymph nodes or skin, and occurring mainly
in people with depressed immune system. It occurs in less than 3 in 100,000 people
in the USA. Cervical cancer is caused by several types of virus, the most common is
human papillomavirus (HPV). Incidence of NHL has increased in an almost parallel
course with the AIDS epidemic and accounts for 2% to 3% of the newly diagnosed
AIDS cases [1] . Patients with HIV infection are noted to develop lymphomas about
100 times more often and Kaposi’s sarcoma about 400 times more often than non-
1
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infected individuals [49].
Lymphomas are cancers that begin in the immune cells and are divided into two
main types: Hodgkins lymphomas (HLs) and non-Hodgkins lymphomas (NHLs).
HLs are named after Dr.Thomas Hodgkins who first described them and are marked
by Reed-Sternberg cells [3] whereas NHLs are the large and diverse group of can-
cers of the immune cells. NHLs start in the lymphocytes and are characterised as
either slow-growing, that is the non-aggressive or fast-growing (aggressive) and are
noted to be more common than the HLs.
1.2 Motivation
AIDS-related non-Hodgkin’s lymphomas (AIDS-NHLs) are the cause of death in
approximately 16% of HIV-infected individuals [16, 37, 52]. The non-Hodgkin’s
lymphoma (NHL) facts shows that about 71,000 patients will be diagnosed with
NHL in 2015, and approximately 19,500 patients will die in the United States [3].
This implies that the disease continues to be a threat despite the advances in highly
active antiretroviral therapy (HAART) [11, 17, 43, 48], since the most common type
includes the diffuse large B-cell lymphoma which mostly occur due to HIV infec-
tion.
Year Total No. of Patients No. of HIV-seropositive Patients No. of HIV-seronegative Patients Percentage (%) of HIV Positive with NHL
1993 20 19 1 5
1994 20 18 2 10
1995 18 15 3 16.7
1996 28 25 3 10.7
1997 18 14 4 22.2
1998 34 18 16 47.1
1999 22 14 8 36.4
2000 30 16 14 46.7
2001 24 4 20 83.3
2002 40 15 25 62.5
2003 44 17 27 61.4
2004 58 23 351 60.3
2005 54 15 39 72.2
2006 72 17 55 76.4
2007 72 19 53 73.6
2008 76 10 66 86.8
Table 1.1: Source:Moosa Patel.[42]. Patients with non-Hodgkin’s Lymphoma at
Chris Hani Baragwanath Academic Hospital, Johannesburg, South Africa from
1993-2008
Clinical studies, that is, experimental and computational biological studies have
documented a lot of findings in relation to these specific lymphomas as their eti-
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ology and pathogenesis is well documented. On the other hand, mathematical
models that provide an alternative way to study the growth of cancer both HIV-
related and non-HIV related have been precisely developed and the findings have
provided the oncologists with solutions to cancer problems. Despite these findings
from the mathematical models linking experimental to computational biology, peo-
ple living with HIV continue to be at a significantly increased risk for intermediate-
and high-grade B-cell non-Hodgkin lymphoma. This still occurs in the era of ad-
vances in highly active antiretroviral therapy (HAART) [11].
More than a third of HIV-infected individuals residing in sub-Saharan Africa eli-
gible for antiretroviral therapy (ART) receive combined ART [43]. Despite the in-
creased roll-out of combined antiretroviral therapy, a meaningful decrease in the
incidence of AIDS-associated malignancies is yet to be realised [43]. In many poor
communities around the world where anti-HIV drugs are nevertheless available,
anti-cancer treatment is almost non-existent. For example, the estimates regard-
ing access to or coverage of the cytotoxic chemotherapy in sub-Saharan Africa are
largely unknown and neither are they published [43]. The study by Gopal et al. also
indicates that, treatment of haematologic malignancy for instance the HIV-related
NHL in the developed countries is increasingly associated with unparalleled rates
of long-term control and survival. Contrarily, in sub-Saharan Africa, the mecha-
nisms for diagnosis, treatment and palliating of this disease are still inadequate [17].
Out of the 54 sub-Saharan Africa countries, only 21 have operational radiotherapy
service units and map showing the distribution of these services is highlighted in
[17]. Securing chemotherapies by the sub-Saharan African governments due to the
limitation in their supply may be less practicable as they compete with developed
countries. This may lead to drug shortages for lymphoma treatment in these re-
gions [17].
The delay and misdiagnosis of lymphoma, more specifically the diffuse large B-cell
NHL in HIV patients, remains a major problem in South Africa [48]. Cancer, is
often misdiagnosed as tuberculosis and this implies that patients living with HIV
and HIV-related NHL are only introduced to HAART, instead of receiving the anti-
cancer drugs. A summary of data collected by Puvaneswara et al.[48] on some
patients in the mentioned community is shown in Table 1.
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Regimen
(Study/Year)
Reference
Nos. Pts. ORR(CR/PR) Survival Comments
Dose-
modified oral
chemo.(CWRU
2498/2009)[29]
49 78% (CR 58%PR
30%)
MST 12.3
months.
(33% 1-yr)
Only published prospective treatment trial of
AR-NHL in sub-Saharan Africa; conducted
comparable HIV therapeutic era as ACTG 142
trial [45]; 6% treatment mortality rate
Uganda Cancer
Institute (NHL
study/2011)[35]
154 (32%
HIV+)
No response data
provided or types
of chemotherapy
MST 61 days
(13% 1-yr)
Largest retrospective study on NHL includ-
ing HIV(-) and HIV(+) case ever reported with
treatment and outcome data. Only 60% had
acceptable clinical staging
Stellenbosch
University[19]
512 (4 HIV+) Overall CR range
46-75% for all sub-
types; chemother-
apy regimens not
reported
MST 10
months (50%
1-yr)
Comprehensive retrospective study of spec-
trum lymphoproliferative disorders at amajor
private referral centre in Cape Town. Only 4
cases (<1% were HIV(+)) MST is for the 4 AR-
NHL cases
Table 1.2: Source: Mwamba et al. [43]. A summary of clinical data on the treatment
of AIDS-related non-Hodgkins lymphoma (AR-NHL) in sub-Saharan Africa. The
abbreviations used: CWRU: Case Western Reserve University, and ACTG: AIDS
Clinical Trials Group; Nos. Pts.: number patients; ORR: objective response rate;
(CR/PR): complete response/partial response; MST: median survival time, 1-yr :
1-year survival rate and OS: overall survival; and cART: combination antiretroviral
therapy.
In view of the inadequate supply of chemotherapeutic drugs and radiotherapy
equipments as well as increased incidences of NHL misdiagnosis and lack of trained
personnel in Sub-Saharan Africa [17, 43, 48], there is dire need to understand the
role played by HIV and its treatment with the HAART in the dynamics of the AIDS-
related NHLs due to the increased roll-out of the HAART in these regions. More
precisely, we address the question that arises; Can RTIs and PIs be combined in a
way that will reduce the cancer (NHL) load, while maintaining acceptable level of
CD4+ T cells? We also seek to understand the role of T cells in killing the cancer
cell, since in HIV infected individuals, the reduced number of T cells exacerbates
cancer growth.
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1.3 Objectives of the study
The main objective of this study is therefore, to use mathematical models to investi-
gate the dynamics of HIV-related non-Hodgkin’s lymphoma in the presence of HIV
and HIV treatment. In order to achieve this, we develop a mathematical model that
investigates the relationship between cancer growth, host tissues and the immune
system components in the presence of HIV. More precisely, we aim;
i. To describe the NHL-immune system interactions through a conglomerate of
cytokines in the presence of HIV and its treatment.
ii. To formulate a workable mathematical model for the process with the inclu-
sion of anti-HIV drugs in the model.
iii. To carry out a detailed mathematical analysis both analytically and numeri-
cally and establish the existence of cancer-free and cancer-persistence states.
iv. To extend the model to include the anti-cancer drugs that is, chemotherapy.
v. To investigate the effects of combined use of reverse transcriptase inhibitors
(RTIs) and protease inhibitors (PIs) in the highly active antiretroviral therapy
(HAART) regimen on cancer cell density through numerical analysis.
vi. To investigate the effects of the chemotherapeutic treatment on the HIV-related
NHL dynamics through numerical analysis.
The rest of the thesis is therefore organized as described in the following section.
1.4 Project outline
We explore the biology of HIV-related non-Hodgkin’s lymphoma and review rele-
vant mathematical models which include cancer-immune system interactions mod-
els and HIV-related cancer-immune system interactions models in Chapter 2. In
Chapter 3 we present the main model for the role of HIV and its treatment on the
dynamics of HIV-related non-Hodgkin’s lymphoma. The model is formulated and
analysed in this chapter where the numerical simulations and deductions from the
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results obtained are also presented. We focus on the stability and bifurcation anal-
ysis to establish the existence of the equilibria and to understand the behaviour of
the model formulated in the study. We extend the model to include chemotherapy
as a cancer treatment in Chapter 4. Here, we explore the effect of the two types of
drugs (RTIs and PIs) combination on the HIV-related NHL load and the effects of
chemotherapeutic drugs as well. We present our numerical simulations and dis-
cussions of the results for the extended model in this chapter. In Chapter 5, we
conclude the study with discussions and pertinent recommendations.
Stellenbosch University  https://scholar.sun.ac.za
Chapter 2
Literature review
In order to develop a cancer mathematical model, knowledge in two different ar-
eas is ineluctable; understanding of the relevant biological phenomena and the re-
sponse processes involved in the cancer growth and the appropriate mathematical
tools employed in order to obtain logical qualitative and quantitative predictive
results. We thus review some previously studied cancer mathematical models as
a basis to our work and afterwards, explore the biology of the HIV-related non-
Hodgkin lymphomas with the inclusion of HIV treatment with highly active an-
tiretroviral therapy (HAART).
2.1 Cancer models
Various research in the field of mathematical biology have considered the dynamics
of cancer-immune interactions in the presence of HIV for the HIV-related malignan-
cies both at population level and cell level (inhost). Similar studies have been done
for other types of malignancies (non-HIV related). We will therefore, consider a few
of these studies so far done as a preliminary to our work.
The first mathematical model for cancer dynamics was studied by De Boer and his
colleagues [9], where they modeled the anti-cancer immune response under the im-
pact of external cytokine IL-2 that is, exogenous IL-2 in the form of ordinary differ-
ential equations. They deduced from their work that early T helper activity highly
increases the magnitude of immune response and the cytotoxic effector cells respon-
sible for tumor eradication is dependent on tumor-antigenicity. Kirscher et al. [33]
7
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went ahead to model similar cellular interactions considering both the naturally
produced (endogenous) and the exogenous IL-2. Following were L.G. de Pillis and
his colleagues [38] who included the chemotherapeutic effect. They formulated a
model cultured with chemo-immunotherapy under the influence of exogenous and
endogenous IL-2. Their results showed that the more effectively CD8 T cells taken
from peripheral blood kill tumour cells, the more useful immunotherapy may be in
conjunction with chemotherapy [38].
Hashmi et al. [24], further developed a mathematical model for cancer regression
by incorporating cancer cells, effector cells, natural cell populations cultured with
chemotherapy and IL-2 under the influence of immunodeficiency virus. The model
developed by Hashmi and his colleagues is represented in Figure 2.1 and system
(2.1.1) represents the dynamical equations developed. Though, no numerical jus-
tification was given by the researchers, their theoretical interpretation showed that
the analysis of their model with the inclusion of the treatment as explained may
give better cancer regression efficiency that is, has potential to reduce cancer.
dT
dt
= r1T(1− bT)− aETg2 + T − KT(1− e
−ξM)T,
dN
dt
= r2N(1− eN) + kT
(
1− T
Tc
)
− KN(1− e−ξM)N,
dE
dt
= cT − µ1E + p1EIg1 + I − αVE− KE(1− e
−ξM)E,
dI
dt
=
p2TE
gE + T
− µ2 I,
dV
dt
=
f V
h +V
− βVE− µ3V,
dM
dt
= −γM +VM(t).

(2.1.1)
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Effector Cells
E(t)
Chemotherapy
        M(t)
Tumor Cells
       T(t)
Immunodeficiency
     Virus
        V(t)
Interleukin IL-2
        I(t)
Natural Killer 
     Cells
       N(t)
Figure 2.1: Source: Hashmi et al.[24]. Schematic diagram showing the interaction
between the cellular populations of the cancer cells,Natural Killer cells and Effector
cells cultured with chemo-immunotherapy and Interleukin IL-2 under the impact
of Immunodeficiency Viruses. We have used the bold lines with square head ar-
rows to represent inhibition or killing of the cells by either the chemotherapy or the
effector cells incase of the tumor. The arrow heads have been used to represent cell
activation.
Fathala et al. [49] on the other hand, introduced ODE and DDE models which
described the tumor-immune system interactions in vivo in the presence of CD4+
T cells HIV infection. In their study, they considered the following populations;
tumor cells, healthy CD4+ T cells, infected effector cells and the free viral particles.
Arciero et al. [5] later developed a model which consisted of a system of ODE’s that
describe the interactions between tumor cells, immune cells and the cytokines IL-2
and TGF-β. They described in their work, the essence of TGF-β in stimulation of
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tumor growth and suppressing of immune system by inhibiting the activation of ef-
fector cells. Their results further showed how treatment with small interfering RNA
(siRNA) is able to suppress the tumor by returning it to passive (non-aggressive
state) that might not evade immune surveillance under some conditions.
Louzon et. al.[39] recently developed and discussed a model describing the pancre-
atic cancer-immune system interaction. They studied the profile of cancer growth
and how different treatments considered in their work affect the cancer growth.
Their study comprised of populations viz: cancer cells, immune system for in-
stance, macrophages and the CTLS, and cytokines. Their results showed that the
treatments aimed at suppressing cancer growth are only effective if the immune
induced death lies within a specific range. This implies that, the parameter repre-
senting the immune response plays an important role in control of cancer growth.
This analysis might be of great importance to the medical sector since it implies that
bringing the parameter to some value may not be enough since we will still have
the existence of both aggressive state and non-aggressive state. The parameter must
thus be increased upto some value to ensure existence of non-aggressive cancer or
no cancer cells in the system.
In this dissertation, we are motivated by the work in [39], in describing a model
aimed at studying the role played by HIV and its treatment in the growth of NHLs.
Most of the research have always focused on modelling either cancer dynamics in
a host immune system, HIV dynamics or the interaction of the cancer cells with
the immune system in the presence of HIV in vivo [33, 49, 61] however, most im-
portantly none of these studies to the best of our knowledge have incorporated all
the cytokines present in the tumor microenvironment in an HIV-tumor coinfection
scenario at individual level (in vivo). We will therefore, consider a combination of
cytokines (which are other factors that might contribute to the occurrence of tumor)
in modelling the role of HIV in the NHL growth. In our study, we consider the
macrophages (pro-inflammatory, M1 and anti-inflammatory, M2), T cells (healthy
CD4+ T cells, HIV-infected CD4+ T cells and CD8+ T cells), the virus and cancer
cells. The cells interact with each other through a conglomerate of cytokines.
We will investigate how these interactions (described in the following section) affect
the growth of the cancer with and without the inclusion of anti-HIV and anti-cancer
therapies most importantly the HAART and to some extent chemotherapy.
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2.2 HIV-related non-Hodgkin’s lymphoma
epidemiology
The hallmark of Human immunodeficiency virus (HIV) is deficiency in CD4+ T
cells, caused by the virus which infects them and causes their destruction. The
disease is characterised as acquired immunodeficiency syndrome (AIDS) when the
number of T cells falls from about 700000 in ml of blood to 200000. Since CD4+
T cells are an important component of the immune defense against diseases and
in particular against cancer, people with advanced stage of HIV are at risk of de-
veloping cancer. This has been particularly observed in the case of non-Hodgkin
Lymphoma (NHL) [26, 42, 56].
Lymphomas are generally white blood cells (T-cell or B-cell lymphocytes) that be-
come abnormal i.e mutate and begin to divide uncontrollably, interfering with the
body’s production of healthy blood cells and ability to fight off infections and other
diseases [28].
AIDS-related NHL, a blood disease which is characterised by abnormal growth
of mutated lymphocytes are consistently derived from B-cells and are character-
ized by extreme aggressiveness. Gu Yian [21] noted that chronic infections for
instance, HIV involve chronic antigenic stimulation by persistent self-antigens or
foreign antigens; this stimulation activates B cells and induces their uncontrollable
growth. Non-Hodgkin’s lymphomas are classified as: AIDS-related Burkitt’s lym-
phoma (AIDS-BL), AIDS-related diffuse large cell lymphoma (AIDS-DLCL) and
AIDS-related primary effusion lymphoma (AIDS-PEL) [14].
The abnormal growth of these cells is a series of events that involves a heteroge-
neous assembly of cells and the immune response to the cancer growth exist in
cancer-bearing hosts. Cancers often induce dysfucntion in the response mecha-
nisms by impairing the regulatory networks driven by cytokines. Cytokines are
regulatory molecules that are secreted by various cell types for the regulation of
immune response to infection. They are messenger molecules that cells use to com-
municate. The ones that play a crucial role in the pathological processes of can-
cers are classified as interleukins (ILs), tumor necrosis factors (TNFs), transform-
ing growth factors (TGFs), interferons (IFNs) and colony-stimulating factors (CSFs)
[27]. Cytokines influence the biology of cancers either by promoting cancer growth
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or impairing anticancer responses [13]. There is a disruption of normal cytokine
regulatory networks in the presence of immune suppression. This often leads to
altered immune responses and can contribute to the development of malignant out-
growths [46].
Research into the cytokines expressed in AIDS- related lymphomas has shown el-
evated serum levels of IL-6 and IL-10 in HIV infected individuals [13, 14, 47]. Hu-
man tumor microenvironment includes macrophages and these tumor associated
macrophages (TAMs) are phenotypically classified as M1 and M2 [18, 25]. M1
macrophages are the macrophages that have undergone cell activation in response
to interferon (IFN) while the M2 are those that have undergone activation in re-
sponse to IL-4. The M1 macrophages are associated with acute inflammation and
T-cell immunity and are characterized by the expression of high levels of pro- in-
flammatory cytokines. The M2 macrophages are anti-inflammatory and are asso-
ciated with the promotion of cancer growth [18, 25, 50]. TAMs can switch type
between pro-inflammatory M1 and anti-inflammatory M2 in the tumor environ-
ment [25]. IL-6 has been identified as a key cytokine for the B-cell NHL’s growth
and survival [65]. As indicated in [32], TGF-β is likely to contribute to the deficit in
T-cell surveillance. IL-6 and TGF-β induce polarization of M2 into M1 macrophages
and promote an immunosuppressive environment [65]. One of the most important
features of M1 macrophages is the production of a T-cell stimulating cytokine IL-12
which enhances natural killer cell activities by activation of CD8+ effector T cells
[62]. M2 macrophages produce IL-10 cytokines which down regulates the activi-
ties of IL-12, and thus inhibits the activation of T cells by IL-12 [6, 19, 59]. It has
also been shown that IL-12 induces IL-10 production as a negative feedback for
IL-12-induced immune response [58, 59]. Interleukin 2 (IL-2) is a cytokine signaling
molecule in the immune system naturally produced mainly by the CD4 T-cells. IL-2
may be administered from external sources that is, exogenous IL-2 while the nat-
urally produced ones are the endogenous. Our study focusses on the endogenous
IL-2. CD4+ T cells produce the cytokine IL-2 which induces growth, proliferation
and activation of both CD4+ T cells and CD8+ T cells. CD8+ T cells are also called
cytotoxic cells (CTL) and they are directly involved in killing cancer cells [36]. The
CD8 effector cells are also responsible for the production of chemokines which in-
hibit the infection of the macrophages by the virus [4].
The greatest risk factor for the development of NHL is immune deficiency. Infec-
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tion by HIV, is typified by a marked deficiency of CD4+ T cells and a persistent
stimulation of B cells [20], therefore NHL risk in people with HIV infection is high.
More than 90% of HIV-associated NHLs are derived from B cells, and the majority
are high-grade and extranodal [20]. We thus focus on the NHL derived from B cells.
We schematically represent the process described above in Figure 2.2.
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Figure 2.2: Transmission dynamics of HIV-related NH Lymphoma.
As HIV progresses to AIDS (latest stage of HIV), a major concern is the number
of CD4+ T cells due to the destructive effect of the HIV on these cells. They are
the primary virus target and their depletion is of concern since immunodeficiency
arises primarily as a result of the depletion. In HIV-infected patients, the extracel-
lular virus infects the CD4+ T cells and afterwards become productively infected
and thus produce more virions whose presence in the host immune system has ad-
verse effect on the elimination of the cancer since it is able to escape the immune
’surveillance’. The depletion of these cells is very vital in this study since it results
in an immunosuppressive environment.
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An individual with HIV who develops cancer, should be treated both for cancer
and HIV. Highly active antiretroviral therapy (HAART) is the most effective anti
HIV drug that have long been used to curb HIV infection (by reducing viral load
and hence reduction in the depletion of CD4+ T cells). Since we are dealing with
an HIV-related cancer, considering the HAART is important. We therefore con-
sider in this study, the treatment of HIV with HAART which has at least two dif-
ferent antiretroviral drugs (ARVs) i.e. nucleotide reverse transcriptase inhibitors
(NRTIs) and one non-nucleotide reverse transcriptase inhibitors (NNRTIs) or a pro-
tease inhibitor (PI). The reverse transcriptase inhibitor (RTI) and protease inhibitor
(PI) drugs are therefore the important components of HAART for the treatment of
AIDS. RTI works by blocking the reverse transcription of viral DNA and can there-
fore effectively prevent the target cell from becoming productively infected by the
free virus. It is worth noting that the inhibition process by RTI occurs after the
virus has been attached to the cell and therefore the drug does not directly affect
the infection rate of the target cells. On the other hand, PI drug blocks the action
of HIV protease by preventing it from cleaving the viral polyprotein into functional
sub units which ultimately prevent the formation of new copies of functional virus.
Cancer treatment is discussed later in Chapter 4 where we extended the model.
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2.3 Summary
In this chapter we have reviewed some selected cancer models as a basis of our
work and looked into the biology of cancer-immune system interactions of HIV-
related NHL. To this point, we will therefore employ the biological phenomena and
response processes involved in the non-Hodgkin’s lymphoma growth and math-
ematical ideas discussed in this chapter to formulate our mathematical model in
Chapter 3 that follows.
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HIV-related non-Hodgkin model with
HIV treatment
3.1 Introduction
Considering the interactions of immune cells, cytokines, HIV and cancer cell (NHL)
described in Chapter 2, we develop a mathematical model that describes the inter-
action incorporating treatment with the RTI and PI drugs; components of HAART.
A mathematical model is a description of a system using mathematical language.
Our model focuses on the role of T cells in killing the cancer cell, since in HIV in-
fected individuals, the reduced number of T cells exacerbates cancer growth. We
then show that the model is positively invariant, hence, both mathematically and
biologically well posed and afterwards carry out mathematical analysis. We accom-
plish this by determining the steady states and numerically determine the stability
of the steady states (both cancer-free and cancer-persistent). Recent studies for in-
stance, the study by Louzon et al. [39] on pancreatic cancer show that the parame-
ter representing immune-cancer cell induced death i.e responsible for the immune
response play an important role in mathematical modelling of cancer since it in-
fluences the dynamics of the cancer states. We will therefore investigate the role
played by this parameter in our model in the presence of HAART and without the
HAART by numerically carrying out bifurcation analysis with this specific param-
eter as our bifurcation parameter. We will focus on the stability and bifurcation
analysis to establish the existence of the equilibria and to understand the behaviour
16
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of the model formulated in the study. We also carry out sensitivity analysis on our
model parameters to find out the effects of these parameters on the cancer dynam-
ics.
3.2 Mathematical model formulation
We first postulate a mathematical model driven by the following variables: tumor
associated macrophages (pro-inflammatory M1 and anti-inflammatory M2), T cells
(healthy CD4+ T cells, infected CD4+ T cells, and CD8+ T cells), HIV virus, V and
the cancer cells, C. The mathematical model is based on the network described in
Figure 3.1.
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Figure 3.1: Schematic representation of interactions of cells and cytokines in HIV-
NH Lymphoma. We have macrophages M1, M2, T-cells (immune cells) T4, Ti4, T8,
cytokines (Tβ, I6, I10, I12, I2), the cancer cells, C and HIV, V. The pool of viruses V,
through infection, affects the movement of the healthy CD4+ T cells, T4 into the
infected CD4+ T cells, Ti4 compartment. We have used the dotted lines with arrow
heads to represent cytokine production, and cell activation and with square head to
represent inhibition. The bold lines with arrow head represent induction, transition
or activation, and with square head represents killing.
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Table 3.1 lists the variables used in the model and the parameters used in formulat-
ing our model equations are summarised in Table 3.2.
Table 3.1: Variables and their units
Variable Description Units
M1 density of pro-inflammatory tumor associated macrophages cells/ml
M2 density of anti-inflammatory tumor associated macrophages cells/ml
T4 density of healthy CD4+ T cells cells/ml
Ti4 density of virus-infected CD4
+ T cells cells/ml
V density of extracellular HIV virus/ml
T8 density of CD8+ T cells cells/ml
C density of cancer cells cells/ml
Tβ concentration of transforming growth factor (TGF-β) pg/ml
I6 concentration of interleukin 6 (IL-6) pg/ml
I10 concentration of interleukin 10 (IL-10) pg/ml
I12 concentration of interleukin 12 (IL-12) pg/ml
I2 concentration of interleukin 2 (IL-2) pg/ml
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Table 3.2: Symbols, description and units of the parameters used in the model.
Parameter Description Units
α1 production rate of TNF-α due to cancers cells pg/cell day
α2 production rate of IL-2 due to CD4+ T cells pg/cell day
α6 production rate of IL-6 due to cancers cells pg/cell day
α10 production rate of IL-10 due to M2 pg/cell day
α12 production rate of IL-12 due to M1 pg/cell day
d1 degradation rate of TNF-α day−1
d2 degradation rate of IL-2 day−1
d6 degradation rate of IL-6 day−1
d10 degradation rate of IL-10 day−1
d12 degradation rate of IL-12 day−1
s1 influx rate of M1 day−1
s2 influx rate of M2 day−1
s3 production of CD4+ T cells by the sources day−1
k1 per capita death rate of M1 day−1
k2 per capita death rate of M2 day−1
λ1 transformation rate of M1 by TNF-α ml/pg day
λ2 transformation rate of M2 by IL-6 ml/pg day
ν transition rate from M2 to M1 ml/pg day
β1 activation rate of T cells by IL-12 pg/cell day
β2 proliferation rate of T cells by IL-2 pg/cell day
β3 loss of cancer cells day−1
K2 saturation constant of proliferation by IL-2 pg/ml
K10 saturation constant for anti-proliferation by IL-10 pg/ml
e modification parameter
µ1 per capita death rate of uninfected CD4+ T cells day−1
µ2 infection rate of CD4+ T cells due to infiltration by free
viruses
day−1
µ4 per capita death rate of CD8+ T cells day−1
µv clearance rate (loss) of free viruses day−1
µ5 per capita death rate of infected CD4+ T cells day−1
δ2 lytic death rate of infected CD4+ T cells day−1
N Virions produced during a lifetime by an infected CD4+ T
cells
r cancer growth rate day−1
C0 maximum cancer density
ζr measure of efficacy of reverse transcriptase inhibitor (RTI)
ζP measure of efficacy of protease inhibitor (PI)
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3.2.1 Model equations
We now present the model equations by the following system of non-linear ordi-
nary differential equations (ODEs). We consider cytokines dynamics and the cells
dynamics.
3.2.1.1 Cytokine equations
In model system (3.2.1), the ordinary differential equations track the dynamics of
the cytokines, where the positive terms show the secretion of the cytokines by re-
spective cells into the cancer environment while the negative terms indicate the
natural decay of the cytokines which occurs in a short time-scale as opposed to the
dynamics of the cell population. The secretion and decay rates of the cytokines de-
pend on the size of the cells causing the change. This assumption follows from the
study by Louzoun et al. [39].
dTβ
dt
= α1C− d1Tβ,
dI6
dt
= α6C− d6 I6,
dI10
dt
= α10M2 − d10 I10,
dI12
dt
= α12M1 − d12 I12,
dI2
dt
= α2T4 − d2 I2,

(3.2.1)
Tβ and I6 are produced by cancer cells [14, 39, 52], I12 and I10 are produced pri-
marily by M1 and M2 macrophages [39, 58, 59] and I2 is produced by T4 cells [36].
Parameters, αi represent the production rates by the respective cells, whereas di are
the respective cytokine decay rates.
3.2.1.2 Immune cell equations
The dynamics of macrophages are given by the following equations
dM1
dt
= s1 − k1M1 + νM2 − (λ1Tβ + λ2 I6)M1, (3.2.2)
dM2
dt
= s2 + (λ1Tβ + λ2 I6)M1 − k2M2 − νM2, (3.2.3)
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Here s1 and s2 are source terms for M1 and M2 macrophages, ν represents the un-
biased interchange between these two macrophage phenotypes, and (λ1Tβ + λ2 I6)
is the rate by which additional transformation occurs from M1 to M2 and it is ac-
tivated by cytokines TGF-β and IL-6 [39]. The natural deaths of the macrophages
M1 and M2 are assumed to be directly proportional to the concentration rate of the
macrophages thus occur at the per capita rates k1 and k2 respectively.
The density of CD4+ T cells, T4 satisfies the equation
dT4
dt
= s3 + β1
I12M1
K10 + I10
+ β2
I2T4
K2 + I2
− µ1T4 − (1− ζr)µ2VT4, (3.2.4)
with a source term s3 (from a source such as the thymus) and apoptosis rate µ1. T4
is further activated (from naive T cells) by I12 while in contact with M1 due to the
molecule, major histocompatibility complex, class II (MHC-II) found on the surface
of M1 [23, 39] at a rate β1. The MHC-II molecule found on the surface of M1, an
antigen presenting cell (APC) together with IL-12 activates the naive T helper cells,
where the former also aid in the priming of the naive T helper cells into effector T
cells and memory T cells. This process is resisted by IL-10. The third term on the
right-hand side of equation (3.2.4) is the proliferation enhanced by I2 [36], and the
fourth term is the natural death of T4 cells. We assume the proliferation is saturated
thus we use the Michaelis-Menten kinetics in the proliferation term. The last term
is the depletion of T4 as a result of invasion by external virus, a process which
is reduced by RTI drug as represented by the factor 1− ζr, where 0 ≤ ζr ≤ 1. If
ζr = 1, then the RTIs offer 100% protection while if ζr = 0, zero protection is offered.
It is worth noting that the inhibition process by RTI occurs after the virus has been
attached to the cell and therefore the drug does not directly affect the infection rate,
µ2 of the target cells.
The density of infected T4 cells, Ti4 satisfies the equation
dTi4
dt
= (1− ζr)µ2VT4 − µ5Ti4, (3.2.5)
where in µ5 we included both the natural death rate and the burst rate δ2 of the
infected T4 cells, hence µ5 > δ2. We assume that without HIV drugs, upon burst of
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one infected T4 cell, N virions are released. However, this number will be decreased
by a factor 1− ζp, (0 ≤ ζp ≤ 1) under treatment with PI drug. Hence
dV
dt
= (1− ζp)Nδ2Ti4 − µvV, (3.2.6)
where µv is the death, or degradation rate of extracellular virus. Similar conclusions
can be drawn for ζp = 0 and ζp = 1 as done for ζr.
T8 cells are activated by I12, a process inhibited by I10 [19, 58, 59] and I2 [36]. e
included in the first term is a modification parameter which represents the prolif-
eration potential of CD8+ T cells when compared to that of CD4+ T cells when
influenced by I12 and I10. Since HIV does not invade into T8 cells, we have the
following equation;
dT8
dt
= eβ1
I12
K10 + I10
+ β2
I2T8
K2 + I2
− µ4T8, (3.2.7)
where the loss of the cells is at a rate µ4 given by the term µ4T8 assuming direct
proportionality of the rate to the concentration of the CD8+ T cells.
As in [39], we assume the dynamics of the cancer is governed by two processes: i.e.
intrinsic growth of the cancer cells and the elimination due to the cytotoxic effector
cells. Therefore, considering equation (3.2.8) describing the cancer dynamics, the
first term models the growth of the cancer which we assume as most of the living
organisms, follows universal law with r being the growth rate, C0, the maximum
size of the cancer cells and the total body mass of the cancer cell is represented by
C. For greater elucidation on the growth term, see [22, 39]. The killing rate of the
cancer cells by T8 cells occurs at a rate β3 and follows the mass-action law.
dC
dt
= rC
3
4
(
1−
(
C
C0
) 1
4
)
− β3CT8. (3.2.8)
The parameters in the model system described in equations (3.2.1) - (3.2.8) are all
assumed to be non-negative.
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The model equations are thus given by
dM1
dt
= s1 − k1M1 + νM2 − (λ1Tβ + λ2 I6)M1,
dM2
dt
= s2 + (λ1Tβ + λ2 I6)M1 − k2M2 − νM2,
dT4
dt
= s3 + β1
I12M1
K10 + I10
+ β2
I2T4
K2 + I2
− µ1T4 − (1− ζr)µ2VT4,
dTi4
dt
= (1− ζr)µ2VT4 − µ5Ti4,
dV
dt
= (1− ζp)Nδ2Ti4 − µvV,
dT8
dt
= eβ1
I12
K10 + I10
+ β2
I2T8
K2 + I2
− µ4T8,
dC
dt
= rC
3
4
(
1−
(
C
C0
) 1
4
)
− β3CT8,

(3.2.9)
3.3 Model analysis
3.3.1 The simplified model
The first step is to reduce the model into a model that describes the interactions
between cell populations i.e. CD4 cells, CD8 cells, macrophages and the cancer
cells. We assume quasi-steady-state approximation for the cytokines concentration
since in our model system the dynamics occur at different time scales. The dynam-
ics of cytokines ,that is, their secretion and decay is on a much faster scale than
the dynamics of cells and thus we assume they reach their equilibrium almost in-
stantaneously [39]. Hence, we simplify the model (3.2.1) and (3.2.9) by taking the
cytokines dynamics in system (3.2.1) to be at steady state, so that
Tβ =
α1
d1
C, I6 =
α6
d6
C, I10 =
α10
d10
M2, I12 =
α12
d12
M1, I2 =
α2
d2
T4.
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Substituting these cytokines into model system (3.2.9) we obtain
dM1
dt
= s1 − k1M1 + νM2 − γcCM1,
dM2
dt
= s2 + γcCM1 − k2M2 − νM2,
dT4
dt
= s3 +
γ1M1M1
K10 + γ2M2
+ β2
γ3T4T4
K2 + γ3T4
− µ1T4 − (1− ζr)µ2VT4,
dTi4
dt
= (1− ζr)µ2VT4 − µ5Ti4,
dV
dt
= (1− ζp)Nδ2Ti4 − µvV,
dT8
dt
= e
γ1M1
K10 + γ2M2
+ β2
γ3T4T8
K2 + γ3T4
− µ4T8,
dC
dt
= rC
3
4
(
1−
(
C
C0
) 1
4
)
− β3CT8,

(3.3.1)
where γc = λ1
α1
d1
+ λ2
α6
d6
, γ1 = β1
α12
d12
, γ2 =
α10
d10
and γ3 =
α2
d2
,
with the general initial conditions
M1 ≥ 0, M2 ≥ 0, T4 ≥ 0, Ti4 ≥ 0, V ≥ 0, T8 ≥ 0 and C ≥ 0.
The model system (3.3.1) represents the dynamics of the cell population and the
HIV virus in the presence of cytokines in a cancer environment and HIV treatment.
The analysis of system (3.3.1) is therefore central in this study. We state two im-
portant model properties of model system (3.3.1) before embarking on steady-state
analysis.
3.3.2 Model properties
Before commencing the steady-states analysis of the model system (3.3.1), we look
at some properties to ensure existence of biologically meaningful solutions.
3.3.2.1 Positivity of the solutions
We need to ensure that the state variables remain non-negative and solutions of the
system remain positive for all t ≥ 0 given positive initial conditions i.e. to establish
the long term behaviour of the solutions. We thus have the following lemma.
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Lemma 3.3.1. Given the initial conditions M1 ≥ 0, M2 ≥ 0, T4 ≥ 0, Ti4 ≥ 0, V ≥
0, T8 ≥ 0 and C ≥ 0, then the solutions of M1(t), M2(t), T4(t), Ti4(t), V(t), T8(t) and
C(t) remain positive for all t ≥ 0
Proof. Suppose t˜ = sup
{
t > 0 : M1 ≥ 0, M2 ≥ 0, T4 ≥ 0, Ti4 ≥ 0, V ≥ 0, T8 ≥ 0, C ≥ 0
}
∈ [0, t], implying t˜ ≥ 0. The first equation of system (3.3.1) gives
dM1
dt
≥ s1 − k1M1 − γ(t)M1, where γcC = γ(t).
Integration, yields
M1(t˜) ≥ M1(0)e−
[
k1t+
∫ t
0 γ(s)ds
]
+ e−
[
k1t+
∫ t
0 γ(s)ds
] ∫ t˜
0
s1e
[
k1t+
∫ t
0 γ(s)ds
]
≥ 0.
Hence M1 is always positive for all t˜ > 0. Similarly
M2(t˜) ≥ M2(0)e(−(k2+ν)t) + e(−(k2+ν)t)
∫ t˜
0
s2e(k2+ν)t ≥ 0.
Considering the CD4 T cells we have
dT4
dt
≥ s3 −Θ(t)T4, where Θ(t) = µ1 + (1− ζr)µ2V.
The solution of the differential equation is
T4(t˜) ≥ T4(0) exp
[
−
∫ t
0
Θ(s)ds
]
+ exp
[
−
∫ t
0
Θ(s)ds
] (∫ t˜
0
s3 exp
[∫ t
0
Θ(s)ds
])
≥ 0.
Similarly we have
Ti4(t˜) ≥ Ti4(0) exp (−µ5t) ≥ 0.
Also
T8(t˜) ≥ T8(0) exp
[
−
(
µ4t−
∫ t
0
Φ(s)ds
)]
≥ 0, where Φ(t) = β2 γ3T4K2 + γ3T4 .
Hence T4(t˜), Ti4(t˜) and T8(t˜) are positive for all t˜ > 0.
For the virus population we have
dV
dt
≥ −µvV, ⇒ V(t) ≥ V(0) exp (−µvt) ≥ 0.
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Lastly, for the cancer cell population, we have
⇒ C(t˜) ≥ C(0) exp
[
−β3
∫
T8(s)ds
]
≥ 0.
Hence V(t˜) and C(t˜) are positive for all t˜ > 0. This implies that all the state
variables are non-negative and the solutions of our system remain positive for all
t˜ ≥ 0.
3.3.2.2 Feasible region
Since the model examines the dynamics of the cell populations, it then follows that
all the parameters and state variables should be non-negative for a biologically fea-
sible model. We will therefore analyse model system (3.3.1) in the feasible region
Ω. We thus have the following lemma on the region where the system exist.
Lemma 3.3.2. The solution of our system with initial conditions M1 ≥ 0, M2 ≥ 0, T4 ≥
0, Ti4 ≥ 0, V ≥ 0, T8 ≥ 0 and C ≥ 0 are contained (bounded) for all t ≥ 0 in the
biologically feasible region defined by the set
Ω =
{
(M1, M2, T4, Ti4, V, T8, C) ∈ R7+ : M ≤
(s1 + s2)
k
, T ≤ s3 + K
µ
, V ≤ Nδ2W
µv
,
C ≤
 rC 140
r− β3WC
1
4
0
4
 ,
(3.3.2)
with M = M1 + M2 and T = T4 + Ti4 + T8.
Proof. Summing the two macrophage populations from the first two equations of
system (3.3.1) we obtain
d
dt
(M1 + M2) =
dM
dt
≤ s1 + s2 − kM, for k = min {k1, k2} , (3.3.3)
Integration of (3.3.3) yields
M(t) ≤ (s1 + s2)
k
+
(
M(0)− (s1 + s2)
k
)
e−kt.
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When we take the limit supremum of M as t→ ∞, we have
lim
t→∞ sup M(t) ≤
(s1 + s2)
k
= S.
This implies that
M1 ≤ S and M2 ≤ S.
Hence the macrophage population is bounded.
Again considering the sum of the T cell populations we have
dT
dt
≤ s3 + γ1S
2
K10 + γ2S
+ e
γ1S
K10 + γ2S
− µ1T4 − µ5Ti4 − µ4T8,
≤ s3 + γ1SK10 + γ2S (S + e)− µT,
where µ = min {µ1, µ5, µ4} and M1, M2 ≤ (s1 + s2)k = S.
Through integration, we obtain
T(t) ≤ s3 + K
µ
+
(
T(0)− s3 + K
µ
)
e−µt, where K = γ1S
K10 + γ2S
(S + e) .
Therefore
lim
t→∞ sup T(t) ≤
s3 + K
µ
= W.
This implies that T4 ≤W, Ti4 ≤W and T8 ≤W, hence each of the T-cell population
is bounded.
Considering the virus population we have
dV
dt
≤ (1− ζp)Nδ2W − µvV, since Ti4 ≤W.
Integration gives
V(t) ≤ (1− ζp)Nδ2W
µv
+
(
V(0)− (1− ζp)Nδ2W
µv
)
e−µvt.
We also have
lim
t→∞ sup V(t) ≤
(1− ζp)Nδ2W
µv
= Q.
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Hence V(t) is thus bounded.
Lastly, we consider the cancer cell population. From the last equation in system
(3.3.1), we have
dC
dt
= C
[
rC−
1
4
(
1−
(
C
C0
) 1
4
)
− β3T8
]
,
⇒ dC
dt
≤ C
 r
C
1
4
− r
C
1
4
0
− β3W
 , since T8 ≤ s3 + K
µ
= W.
=
C
[
rC
1
4
0 − rC
1
4 − β3W(C
1
4
0 C
1
4 )
]
C
1
4
0 C
1
4
.
Through integration , we obtain
∫ C 140 C 14 dC
C
[
rC
1
4
0 − rC
1
4 − β3W(C
1
4
0 C
1
4 )
] ≤ ∫ dt,
− 4C 140
(r− β3WC
1
4
0 )
 ∫ −14(r− β3WC 140 )C− 34 dC[
rC
1
4
0 − C
1
4 (r− β3WC
1
4
0 )
] ≤ ∫ dt,
− 4C 140
(r− β3WC
1
4
0 )
 ln(rC 140 − C 14 (r− β3WC 140 )) ≤ t,
we thus have
ln
(
rC
1
4
0 − C
1
4 (t)(r− β3WC
1
4
0 )
)
≤
− (r− β3WC 140 )
4C
1
4
0
 t,
−C 14 (t)(r− β3WC
1
4
0 ) ≤ exp
− (r− β3WC 140 )
4C
1
4
0
 t
− rC 140 ,
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C
1
4 (t) ≤
exp
((
− (r−β3WC
1
4
0 )
4C
1
4
0
)
t
)
− rC
1
4
0
−(r− β3WC
1
4
0 )
,
C(t) ≤

rC
1
4
0 − exp
((
− (r−β3WC
1
4
0 )
4C
1
4
0
)
t
)
r− β3WC
1
4
0

4
.
So
lim
t→∞ sup C(t) ≤
 rC 140
r− β3WC
1
4
0
4 = P.
Therefore C(t) is also bounded.
From the above we observe that as t → ∞, M(t) → (s1+s2)k , T → s3+Kµ ,V → Nδ2Wµv
and C →
(
rC
1
4
0
r−β3WC
1
4
0
)4
where M(t) = M1(t) + M2(t) and T(t) = T4(t) + Ti4(t) +
T8(t).
So, for instance if M0 ≤ (s1+s2)k then limt→∞ M(t) = (s1+s2)k . Clearly, (s1+s2)k is the
upper bound of M, i.e. the non-negative solutions of the first two equations of
system (3.3.1) are monotone increasing and are bounded above by (s1+s2)k . On the
other hand, if M0 >
(s1+s2)
k , then the solutions will decrease monotonically and are
bounded below by (s1+s2)k , i.e. they enter or approach the region asymptotically.
Same applies to other state variables in system (3.3.1).
Our invariant region is therefore defined by Ω. Hence, any solution of our system
that commences in the positive orthant R7+ at t ≥ 0 will either remain confined in
the region, enters or approaches it asymptomatically. We therefore deduce that the
region Ω is positively invariant and attracting with respect to model system (3.3.1)
for instance, the system is both mathematically and biologically well posed. That
completes the proof.
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3.3.3 Steady states
Definition 3.3.3. Given a system of differential equations x’(t)=f(t), an equilibrium/steady
state x∗ of this system is a point in the state space for which x(t)=x∗ is a solution for all time,
t.
To obtain this, we set the right hand side of system (3.3.1) to zero, so that
s1 − k1M∗1 + νM∗2 − γcC∗M∗1 = 0, (3.3.4)
s2 + γcC∗M∗1 − k2M∗2 − νM∗2 = 0, (3.3.5)
s3 +
γ1M∗1 M
∗
1
K10 + γ2M∗2
+ β2
γ3T∗4 T
∗
4
K2 + γ3T∗4
− µ1T∗4 − (1− ζr)µ2V∗T∗4 = 0, (3.3.6)
(1− ζr)µ2V∗T∗4 − µ5Ti∗4 = 0, (3.3.7)
(1− ζp)Nδ2Ti∗4 − µvV∗ = 0, (3.3.8)
e
γ1M∗1
K10 + γ2M∗2
+ β2
γ3T∗4 T
∗
8
K2 + γ3T∗4
− µ4T∗8 = 0 (3.3.9)
rC∗
3
4
(
1−
(
C∗
C0
) 1
4
)
− β3C∗T∗8 = 0. (3.3.10)
We start by solving for the steady states M∗1 and M
∗
2 in equations (3.3.4) and (3.3.5)
and we have respectively
M∗1 =
σ1
Λ+ σ2C∗
and M∗2 =
σ3 + σ4C∗
Λ+ σ2C∗
,
where σ1 = (ν+ k2) s1 + νs2, Λ = k1 (ν+ k2) , σ2 = k2γc,
σ3 = k1s2, σ4 = (s1 + s2) γc.
We therefore assume a quasi steady-state for the viral population and thus from
equation (3.3.8) we have
V∗ =
(1− ζp)Nδ2Ti∗4
µv
. (3.3.11)
Substituting V∗ in (3.3.11) into equation (3.3.7) we obtain
Ti∗4
(
(1− ζp)(1− ζr)µ2Nδ2T∗4
µv
− µ5
)
= 0.
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This gives
Ti∗4 = 0 or T
∗
4 =
µvµ5
(1− ζp)(1− ζr)µ2Nδ2 .
From the above, it implies that T4 has one solution given by
T∗4 =
µvµ5
(1− ζp)(1− ζr)µ2Nδ2 .
For Ti∗4 = 0, our system at the steady state relates to HIV-free cancer equilibrium.
Since our objective is to investigate the role of HIV in the NHLs, we therefore anal-
yse hereinafter the steady state in which there is HIV in the system, that is, co-
infection of HIV and the cancer in the presence of HIV treatment.
We now solve for the steady states, E = (M∗1 , M
∗
2 , T
∗
4 , T
i∗
4 , V
∗, T∗8 , C∗) where the state
of the cancer is also influenced by the presence of the HIV in the cancer environ-
ment. Firstly, we substitute the solution T∗4 into equations (3.3.6) and (3.3.9). We
notice that in the solution T∗4 , the number of virions, N, has an effect on the concen-
tration of the CD4+ T cells in the cancer environment, therefore the virus and the
infected T cells play a crucial role in our model.
From (3.3.6) we solve for the solution of V at HIV-related NHL steady state denoted
by V∗ so that
V∗ =
((
s3 +
T∗24 β2γ3
K2+T∗4 γ3
+
γ1σ
2
1
K10(Λ+C∗σ2)2+(σ3+C∗σ4)(Λ+C∗σ2)
)
− µ1T∗4
)
(1− ζr)µ2T∗4
.
From equation (3.3.11), we have
Ti4
∗ = µv

((
s3 +
T∗24 β2γ3
K2+T∗4 γ3
+
γ1σ
2
1
K10(Λ+C∗σ2)2+(σ3+C∗σ4)(Λ+C∗σ2)
)
− µ1T∗4
)
(1− ζp)(1− ζr)µ2Nδ2T∗4
 .
We then obtain the steady state T∗8 as a function of C from equation (3.3.9). We have
T∗8 =
eγ1σ1
[
(1− ζp)(1− ζr)µ2δ2NK2 + γ3µ5µv
][
(1− ζp)(1− ζr)µ2µ4δ2NK2 − γ3µ5(β2 − µ4)µv
]
[K10(Λ+ C∗σ2) + γ2(σ3 + C∗σ4)]
.
Since β2 is the proliferation/activation rate of T8 due to IL-2 and µ4, the decay rate
of T8, it therefore suffice to assume that, for the existence of CD8+ T- cells, the
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proliferation rate must always be greater than the death rate, that is β2 > µ4. This
implies that, the solution T∗8 is positive if and only if
N >
γ3µ5µv(β2 − µ4)
(1− ζp)(1− ζr)µ2µ4δ2K2 = N
∗
crit.
The existence of T∗8 at endemic steady state is subject to N > N∗crit. Therefore, the
virions released per bursting of infected T cell must exceed a certain threshold, N∗crit.
From equation (3.3.10) we have
g(C) = C
[
rC−1/4
(
1− (C /C0 ) 1/4
)
− β3T∗8
]
= 0. (3.3.12)
The solutions of (3.3.12) are
C∗ = 0 or rC−1/4
(
1− (C /C0 ) 1/4
)
− β3T∗8 = 0.
C∗ = 0 corresponds to a cancer free environment.
We define
g(C∗) = rC−1/4
(
1− (C /C0 ) 1/4
)
− β3T∗8 = 0,
for the non-zero steady states.
Once the solutions of T8 are in terms of C, their substitution into the non-zero equi-
libria i.e endemic equilibria result in an implicit function whose solutions can only
be established numerically.
We begin by considering the cancer free steady state. The non-zero solutions of C
are subject to N > N∗crit.
3.3.3.1 Cancer-free steady state, E0
The model given by the system (3.3.1) has a unique feasible cancer-free steady state,
E0 and it represents the state of HIV infection in the presence of HIV treatment with
no cancer cells in the host immune system. It reflects the possibility of cancer de-
velopment prevention by the immune system (i.e the cancers are not able to evade
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the immune system). The state, E0 is therefore given by
Cancer-free equilibrium, E0 = (M∗1 , M
∗
2 , T
∗
4 , T
0∗
4 , V
∗, T∗8 , C∗), where
M∗1 =
σ1
Λ
, M∗2 =
σ3
Λ
, T∗4 =
µvµ5
(1− ζp)(1− ζr)µ2Nδ2 , C
∗ = 0,
Ti∗4 =
s3
µ5
+
β2γ3µ
2
vµ5
((1− ζr)(1− ζp)NK2µ22δ2 + γ3µ5µvµ2)((1− ζr)(1− ζp)Nδ2)
+
γ1σ
2
1
Λ2K10µ5 +Λγ2µ5σ3
− µ1µv
(1− ζr)(1− ζp)Nδ2µ2 ,
T∗8 =
(eγ1((1− ζp)(1− ζr)µ2δ2NK2 + γ3µ5µv)σ1)
((1− ζp)(1− ζr)µ2µ4δ2NK2 + γ3µ5(µ4 − β2)µv)(K10Λ+ γ2σ3) ,
V∗ = (1− ζr)Nδ2s3
µvµ5
+
β2γ3µvµ5
(1− ζr)(1− ζp)2NK2µ22δ2 + γ3µ5µvµ2
+
Nδ2γ1σ21
Λ2K10µvµ5 +Λγ2µvµ5σ3
− µ1
(1− ζp)µ2 .
The existence of cancer-free equilibrium, E0 is subject to N¯crit < N,
where N¯crit = max
{
Ncrit, N∗crit
}
, and
Ncrit =
µ5µvµ1
(1− ζp)(1− ζr)µ2δ2s3
N∗crit =
γ3µ5µv(β2 − µ4)
(1− ζp)(1− ζr)µ2µ4δ2K2 = Ncrit
γ3s3(β2 − µ4)
µ1µ4K2
.
The stability of this state is not easy to show analytically, we therefore use numer-
ical simulations in Section 3.4 to help us assess the local stability of the cancer-free
steady state.
3.3.3.2 Cancer-persistence steady states
The steady-state analysis for the model discussed in this section clearly shows the
existence of some feasible (non-negative) and non-zero cancer equilibria (cancer-
persistence steady states). However, due to mathematical intractability we are un-
able to explicitly express the endemic states in terms of the model parameters. We
resort to numerical simulations.
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3.4 Numerical simulations
3.4.1 Parameter estimation.
Table 3.3 provides the description and values of all the parameters that appear in
model system (3.3.1). Due to lack of data, the parameter values used in the nu-
merical simulation were taken from the literature, although not always from cancer
experimental data. Some of the parameters were estimated as follows;
We assume that at steady state of HIV infected person, when he/she still appears
to be normal, T4 = 500000 cells/ml. Since µ1 = 0.02/day [61], from the cancer-free
steady state equation s3− µ1T4 = 0 we then get s3 = 10000 cells/ml day. In normal
healthy individual at steady state, the average monocyte content is 400000cells/ml
[2]. We assume that monocytes differentiate mostly into M1 macrophages as they
move from the blood into the tissue, thus take M1 = 400000cells/ml. From the
cancer-free steady state equation s1 − k1M1 = 0 and k1 = 0.02/day, we get s1 =
8000 cells/ml/day. It is known that tumor attracts myeloid derived suppressor cells
(MDSC), cells that have similar behaviour to M2 cells [54]. We identify MDSC with
M2, and for simplicity consider this source of macrophages as a source term s2. We
assume that this source is small in comparison to the source of M1 macrophages,
and take s2 = s1/10 = 800cells/ml/day. Since k2 = 0.008/day, the steady state
equation s2 − k2M2 = 0 yields the steady state density M2 = 100000cells/ml. We
take the values of parameters λ1 and λ2 to be 0.075 day−1 as in [64]. We finally take
N = 1000, although this number varies in different studies [61].
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Parameter Description Baseline Values Min Values Max Values Units Baseline Source
α1 production rate of TGF-β due to cancers cells 7× 10−4 6.8× 10−4 7.5× 10−4 pg/cell day [5, 60]
α2 production rate of IL-2 due to CD4+ T cells 5 4 6 pg/cell day [5, 33]
α6 production rate of IL-6 due to cancers cells 7× 10−5 5× 10−5 8× 10−5 pg/cell day Estimated
α10 production rate of IL-10 due to M2 5× 10−4 4.9× 10−4 5.3× 10−4 pg/cell day [29, 30, 64]
α12 production rate of IL-12 due to M1 3× 10−2 2.9× 10−2 3.1× 10−2 pg/cell day Estimated in [29]
d1 degradation rate of TGF-β 10 9 11 day−1 Estimated in [5]
d2 degradation rate of IL-2 10 9 11 day−1 [33, 51]
d6 degradation rate of IL-6 0.173 0.1 0.2 day−1 [40]
d10 degradation rate of IL-10 5 3 6 day−1 [29]
d12 degradation rate of IL-12 1.188 1 2 day−1 [29, 45]
s1 influx rate of M1 8000 7500 8500 day−1 Estimated
s2 influx rate of M2 800 750 850 day−1 Estimated
s3 production of CD4+ T cells by the sources 1.0× 104 9.9× 103 1.10× 104 cells/ml day Estiamted
k1 per capita death rate of M1 0.02 0.01 0.04 day−1 [29]
k2 per capita death rate of M2 8× 10−3 7× 10−3 9× 10−3 day−1 [29, 31]
λ1 transformation rate of M1 by TGF-β 0.075 0.07 0.08 day−1 Estimated in [64]
λ2 transformation rate of M2 by IL-6 0.075 0.07 0.08 day−1 Estimated in [64]
ν transition rate from M2 to M1 5× 10−2 4× 10−2 6× 10−2 day−1 [57, 64]
β1 activation rate of T cells by IL-12 1× 106 9× 105 1.1× 106 cells/ ml day [23]
β2 proliferation rate of T cells by IL-2 0.1245 0.1 0.2 pg/cell day [5, 33, 34]
β3 loss of cancer cells 10−5 ∼ 10−9 10−5 10−9 day−1 [39, 53, 63] and estimated (10−7)∗
K2 saturation constant of proliferation by IL-2 2× 107 1.9× 107 2.1× 107 pg/ml [33, 34]
K10 saturation constant for anti-proliferation by
IL-10
2.5× 107 2.4× 107 2.6× 107 pg/ml [23]
e modification parameter 0.5 0.4 0.6 Estimated
µ1 per capita death rate of uninfected CD4+ T
cells
0.02 0.01 0.03 day−1 Estimated in [61]
µ2 infection rate of CD4+ T cells due to infiltra-
tion by free viruses
2.4× 10−8 2× 10−8 3× 10−8 ml/ day Estimated in [61]
µ4 per capita death rate of CD8+ T cells 0.03 ∼ 0.0412 0.02 0.05 day−1 [33, 34] 0.03∗
µv clearance rate (loss) of free viruses 2.4 2. 3 day−1 Estimated in [61]
µ5 per capita death rate of infected CD4+ T cells 0.26 0.2 0.5 day−1 Estimated in [61]
δ2 lytic death rate of infected CD4+ T cells 0.24 0.2 0.3 day−1 Estimated in [61]
r cancer growth rate 0.18 ∼ 0.19 0.15 0.2 day−1 [5, 33, 34, 63] 0.19∗
C0 maximum cancer density 106 cells/ml [39]
N number of virions released upon burst by an
infected CD4+ T cell
1000 500 1500 cells/ml [61] and assumed
ζr the measure of efficacy of reverse transcrip-
tase inhibitors(RTI)
[0, 1]
ζp the measure of efficacy of protease in-
hibitors(PI)
[0, 1]
Table 3.3: Parameter values used in the numerical simulations and sensitivity anal-
ysis.
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3.4.2 Sensitivity analysis
We carry out sensitivity analysis in order to find out the contribution of vital param-
eters on the model dynamics, most specifically to establish the parameters that have
significant influence on the HIV-related NHL dynamics. We employ, among the
numerous sensitivity methodologies, the Latin Hypercube Sampling (LHS) scheme
which is a form of Monte Carlo stratified sampling technique that can be applied
to multiple variables. The technique used during LHS is sampling without replace-
ment. It is designed to accurately recreate the input distribution through sampling
in fewer iterations when compared to the Monte Carlo Method. LHS allows us to
simultaneously obtain an unbiased estimate of the model output for a given set of
input parameter values. We use the LHS by computation of Partial Rank Correla-
tion Coefficients (PRCC) of each parameter value sampled by LHS scheme, and the
outcome values derived from uncertainty analysis [8].
3.4.2.1 Results
We use the model parameter values defined in Table 3.3 to simulate the full range of
parameters. To achieve this, we employ the LHS technique with 1000 simulations
per run to analyse the sensitivity of the parameters to the dynamics of the cancer
cells. We observe from Figures 3.2 and 3.3, that parameters β1, α12, s1, s2, d12, d1, d10, k1
and K10, mostly associated with the cytokines present in the cancer-immune envi-
ronment have significant influences on the number of cancer cell count, i.e signifi-
cant PRCC. As observed in Figure 3.2, the parameters β1, α12, s1, d1, s2 and d10 have
positive correlation, implying that an increase in the magnitude of these parameters
will result in an increase in the number of cancer cell count, for instance, they have
the potential to aggravate the cancer growth. On the other hand, as observed in Fig-
ure 3.3 parameters d12, k1 and K10 have great potential to considerably minimize the
aggressive growth of the cancer cells when increased (negative correlation). Inter-
vention measures in terms of immunotherapy should therefore aim at controlling
the mentioned parameters in order to curb the cancer growth since the system is
truly sensitive to the change in these parameters.
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Figure 3.2: Partial Rank scatter plots of the ranks for the cancer cell count, C and
each of the sampled input parameters with significant PRCCs using the values in
Table 3.3 and 1000 simulations per run.
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Figure 3.3: Partial Rank scatter plots of the ranks for the cancer cell count, C and
each of the sampled input parameters with significant PRCCs using the values in
Table 3.3 and 1000 simulations per run.
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3.4.3 Numerical results
The results presented below of the numerical simulations for system (3.3.1) were
obtained using Matlab ODE45 Solver which employ simultaneously the fourth and
fifth order Runge Kutta schemes. Unless otherwise stated, parameters are as stated
in Table 3.3. The initial conditions used in the numerical simulations unless stated
otherwise, were set as follows; the initial value for the cancer density was set at;
C(0) = 100 cells/ml while the rest of the state variables used in our model the
initial values were set at their quasi steady-states. For instance, the patients are
assumed to be in homeostasis, constant cell population/concentration.
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(a) With no HIV treatment; ζp = ζr = 0 and
β3 = 2.0 × 10−5 − 5.5 × 10−5 steps of 2.5 ×
10−6
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(b) With HIV treatment; ζp = ζr = 0.8 and
β3 = 2.0 × 10−5 − 5.5 × 10−5 steps of 2.5 ×
10−6
Figure 3.4: The g(C) as a function of C with different values of β3 (rate of cancer
loss in the population) with other parameters as in Table 3.3 and the other variables
at their steady states. No chemotherapy treatment initiated.
Figure 3.4 shows the results of our simulation for g(C) as a function of C, with
different values of cancer killing rate, β3. Every one of the trajectories represents
different parameter value of β3 and the values increase from top to the bottom tra-
jectory/line. The values considered were in the range 2 × 10−5 to 5.5 × 10−5 for
both cases; with and without HIV treatment with a step size of 2.5× 10−6 (arith-
metic distribution). A closer look at the trajectories, interestingly show that HIV
treatment is important in cancer growth control. A typical example is to consider
β3 = 4.25× 10−5 represented by the thicker trajectory. Without treatment we can
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have three possible cancer steady states while one steady state is observed for the
case with treatment.
3.4.4 Bifurcation analysis
This is a qualitative change in the behaviour/ dynamics of a dynamical system
produced by varying a parameter in the equation. Bifurcation occurs when a fixed
point of the system being considered changes its stability. According to [10] we
have the following definition
Definition 3.4.1. Consider a class of ordinary differential equations (ODE’s) that depend
on one parameter δ,
x′ = f (x, δ) (3.4.1)
where f : Rn+1 → Rn is analytic for δ ∈ R, x ∈ Rn. Let x = x0(δ) be a class of
equilibrium points of equation (3.4.1), i.e f (x0(δ), δ) = 0. We now set
y = x− x0(δ),
then
y′ = A(δ)y +O(|y|2),
where A(δ) = ∂ f∂x (x0(δ), δ).
Let δ1, δ2, . . . , δn(δ) be the eigenvalues of A(δ). If for some i, Reδi(δ) changes sign at δ =
δ0, we say that δ0 is a bifurcation point of equation (3.4.1).
From the analysis in Figure 3.4, we observe that the parameter β3 is important in our
model since it plays an effective role in defining the cancer behaviour. We thus in-
vestigate numerically, the bifurcation of the model parameter β3, responsible for the
immune response. The graphs in Figure 3.5, display the bifurcation diagrams for
the treatment and no treatment cases. Figures 3.5(a) and 3.5(b) are plots of the non-
zero steady state solutions of g(C∗) = 0 as a function of the parameter, β3. This anal-
ysis helps in understanding the behaviours of the model, i.e the critical values of
the bifurcation parameter where the behaviour of the model system (4.2.1) changes.
Figure 3.5 shows two saddle node bifurcation points. We observe the existence of
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Figure 3.5: Bifurcation diagram: Non-trivial solutions of g(C∗) = 0 as a function of
β3 with the rest of parameters as in Table 3.3 with the other variables at their steady
states.
multiple equilibria with respect to the different range of values for β3. Considering
Figure 3.5(a), one steady state exists for both β3 < 3.27× 10−5 and β3 > 4.43× 10−5.
These exact values where the bifurcation occurs are obtained from the plots in Fig-
ure 3.4(a). However, for 3.27× 10−5 < β3 < 4.43× 10−5 we have three equilibria.
It is also clear from the figure that the upper branch where β3 < 4.43× 10−5 and
the lower branch of the graph where β3 > 3.27 × 10−5, we have stable equilib-
rium of the cancer whereas for the middle is unstable equilibrium. The same is
evident for Figure 3.5(b) where one solution exists for both β3 < 2.91× 10−5 and
β3 > 3.945× 10−5 and three for 2.91× 10−5 < β3 < 3.945× 10−5. This implies
that for the regions β3 > 4.43× 10−5 in Figure 3.5(a) and β3 > 3.945× 10−5 in Fig-
ure 3.5(b), all the trajectories are attracted to the trivial cancer solution or the non-
aggressive steady state disregarding the initial conditions. For β3 < 3.27× 10−5 in
Figure 3.5(a) and β3 < 2.91× 10−5 in Figure 3.5(b), the aggressive cancer equilib-
rium is an attractor for all the initial conditions.
A consideration of the same initial conditions, say (C, β3) = (1 × 105, 3.5−5), in
Figures 3.5(a) and 3.5(b) yields different long term dynamic results. In the absence
of treatment, the system will eventually settle to the aggressive steady state. On
the other hand, in the presence of treatment, the system settles to a non-aggressive
steady state. This underscores the importance of HIV treatment and early identifi-
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cation of the cancer.
The population dynamics of the cancer cell of our system is depicted in the time
series plot, Figure 3.6, where the solution is observed to stabilize after around 512
years for a value of β3 = 1× 10−7.
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Figure 3.6: Population dynamics of the cancer cells in model system (4.2.1) with
the parameters as in Table 3.3. Initial conditions: M1(0) = 40000 cells/ml,
M2(0) = 10000 cells/ml, T4(0) = 5× 105 cells/ml, Ti4(0) = 0 cells/ml, V(0) = 1000
copies/mL, T8(0) = 100cells/ml and C(0) = 100 cells/ml.
The time series plot in Figure 3.6 is considered for different infection rates, µ2 =
2.4× 10−8 and µ2 = 2.4× 10−5 in the presence of HIV treatment. The results are
presented in Figure 3.7. As seen in Figures 3.7(a) and 3.7(b), for a smaller infection
rate, treatment reduces cancer growth while treatment has no effect on the cancer
growth for high infection rate values. So, treatment alone in the absence of reduced
infection rates does not have a significant impact on cancer growth dynamics.
Figure 3.8 shows the dynamics of the CD8 T cell population. For Figure 3.8(a),
where the infection rate of the CD4+ T cells is low, we observe significant growth
of the CD8 T cells in the presence of treatment. Similarly, as in Figure 3.7(b), no
changes are obtained for higher infection rates.
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(a) µ2 = 2.4× 10−8
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(b) µ2 = 2.4× 10−5
Figure 3.7: Population dynamics of the cancer cells in model system (4.2.1) with
only HAART therapy, with ζr = ζp = 0.5 and the rest of the parameters as in Table
3.3. Initial conditions: M1(0) = 400000 cells/ml, M2(0) = 100000 cells/ml, T4(0) =
5× 105 cells/ml, Ti4(0) = 0 cells/ml, V(0) = 1000 copies/mL, T8(0) = 100cells/ml
and C(0) = 100 cells/ml.
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(b) µ2 = 2.4× 10−5
Figure 3.8: Numerical simulation of model system (4.2.1) for the evolution of the
CD8+ T cells (effector cells) with RTIs and PIs treatment of efficacies, ζr = ζp = 0.5
and the rest of the parameters as in Table 3.3. Initial conditions: M1(0) = 400000
cells/ml, M2(0) = 100000 cells/ml, T4(0) = 5× 105 cells/ml, Ti4(0) = 0 cells/ml,
V(0) = 1000 copies/mL, T8(0) = 100cells/ml and C(0) = 100 cells/ml.
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3.5 Conclusion
In this chapter, we investigated the role of HIV in the model of AIDS-related non-
Hodgkin Lymphoma by considering cytokines, macrophages, CD4+ T helper cells,
CD8+ T effector cells and the virus in the cancer environment. The chapter has
provided some interesting insights as discussed below.
From the numerical analysis, it suffices to deduce that when HIV is present in the
cancer environment and no treatment of the HIV initiated in the patient, for a non-
aggressive cancer state to be achieved the cancer killing rate has to be higher , i.e.
higher immune response as compared to the case where treatment of HIV with
HAART is initiated. This implies that the timing of initiating HIV treatment in
patients with the cancer is an important factor since the cancer can remain in a
non-aggressive state despite lower immune response (the comparison is done with
respect to no treatment case).
The bifurcation analysis shows that treatment plays an important role in shifting
the steady states. We notice that given the same value of parameter β3, the steady
states values decrease when HIV treatment is included in the model system and
for most of the parameter value β3, the existence of only low endemic cancer state
is observed. This implies that, as opposed to the no HIV treatment scenario, the
cancer can be controlled to a non-aggressive state despite low immune response.
We also observe that when the HIV infection rate is low, initiating treatment in
patients with HIV-related NHLs reduces cancer growth. Also, no effective control
of the cancer will be observed despite HIV treatment as long as the cancer killing
rate is small, i.e. weak immune response.
Our model represents a possible long-lasting coexistence of HIV-related NHLs and
HIV, because of the existence of the non-zero equilibria. Despite a patient’s strong
immune response and treatment of the HIV with the reverse transcriptase inhibitors
(RTIs) and protease inhibitors (PIs) drugs of efficacy for instance, 50% in our case,
complete elimination of the cancer by the immune system is actually not possible.
The cancer cell will still remain in the host system unless the cancer elimination rate
is very high, though at a lower state that is not so destructive and thus the patient
survives with the cancer for a longer period of time. This could also explain why
some people live with cancer for many years. Moreover, it can also explain why
late initiation of HIV treatment is not very helpful to NHL patients.
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Having looked at the present model, and deduced that treatment with both PI and
RTI drugs lower the steady state of the cancer, we now incorporate treatment of
cancer with chemotherapy in the model as discussed in Chapter 4 that follows.
This is with regard that an individual with HIV who develops cancer should be
treated for both cancer and HIV. Firstly, we will focus on investigating how to best
combine these two drugs i.e. PIs and RTIs in order to reduce cancer load as much
as possible as well as maintaining the acceptable T-cell level. Later in the chapter,
we will explore the effects of chemotherapeutic drugs on cancer cell dynamics.
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NHL model with HIV treatment and
chemotherapy
4.1 Introduction
In this chapter, we relook at the model presented in Chapter 3, with the inclusion
of chemotherapy. We first aim to establish the concept that drugs available only
against HIV can also be judiciously adjusted to be useful against cancer. As dis-
cussed in Chapter 2, consideration of HIV treatment when dealing with the disease
or diseases that arise due to HIV infection is very vital for any analysis involv-
ing the same. Likewise, individuals with HIV who develop cancer should also be
treated for cancer. We therefore, consider cancer treatment administered to patients
diagnosed with cancer, more precisely NHL which depends on the type, its stage
and prognostic factors [55]. According to [55] the following are the main treatment
types;
i Radiotherapy: use of high energy radiation beams focused on cancerous sites
in order to destroy the cancer cells.
ii Biological therapy: also refereed to as immunotherapy, is the administration
of immune cells to the cancer site (referred to as local immunotherapy) or the
whole body (systemic immunotherapy), in order to incite and strengthen the
immune system.
46
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iii Chemotherapy: a drug administered to kill the tumor cell due to their mode of
action i.e killing cells that divide more rapidly, a feature associated with tumor
cells. These drugs though targeted at the tumor cells, can also be destructive
to other cells in the host immune system. The chemotherapy was discoved
in chemical warfare during World War I and was actually first used in cancer
treatment in the 1940s [7].
The above mentioned therapies are considered for the treatment of NHLs and HLs,
but we will focus on chemotherapy as a means of treatment in this study. Our
model formulation is as described in Chapter 3 except for the inclusion of the ther-
apy parameters in the relevant model equations. We assume that the treatment
will not affect the cytokine equations in our model, therefore for the equations that
govern the model with the inclusion of HIV treatment and chemotherapy we will
consider the final equations in system (4.2.1) where the state variables and the pa-
rameters are described as in Table 3.3.
4.2 Model equations
Following [12, 35], most of the chemotherapeutic drugs are only effective during
certain phases of cell cycle (cell cycle specific) and pharmacokinetics indicate that
the effectiveness of the chemotherapeutic drugs is bounded. We therefore have
the term (1− e−D), a saturation term representing the fraction of the cell killed by a
dose, D of chemotherapy. This prompts the inclusion of the cell dose-response term
QDi = Pi(1− e−D)i for i = M1, M2, T4, Ti4, T8, C.
Since the drug concentration in the bloodstream changes with time due to the
processes involved, i.e absorption, distribution, metabolism and excretion, we in-
clude an equation that tracks that dynamics. Therefore, the terms in the non-
homogeneous equation, dD/dt of system (4.2.1) reflects the rate of change in the
dosage concentration over a given period of time. uin(t) is a function of time that
describes the amount of drug influx into the system and the injection time assuming
intravenous administration whereas dD represents the dug elimination rate. The
drug concentration equation assumes instantaneous distribution of the drug into
all body parts.
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The model with the chemotherapy is thus as follows:
dM1
dt
= s1 − k1M1 + νM2 − γcCM1 − PM1(1− e−D)M1,
dM2
dt
= s2 + γcCM1 − k2M2 − νM2 − PM2(1− e−D)M2,
dT4
dt
= s3 +
γ1M1M1
K10 + γ2M2
+ β2
γ3T4T4
K2 + γ3T4
− µ1T4 − (1− ζr)µ2VT4
− PT4(1− e−D)T4,
dTi4
dt
= (1− ζr)µ2VT4 − µ5Ti4 − PTi4(1− e
−D)Ti4,
dT8
dt
= e
γ1M1
K10 + γ2M2
+ β2
γ3T4T8
K2 + γ3T4
− µ4T8 − PT8(1− e−D)T8,
dV
dt
= (1− ζp)Nδ2Ti4 − µvV,
dC
dt
= rC
3
4
(
1−
(
C
C0
) 1
4
)
− β3CT8 − PC(1− e−D)C,
dD
dt
= uin(t)− dDD

(4.2.1)
where γc = λ1
α1
d1
+ λ2
α6
d6
, γ1 = β1
α12
d12
, γ2 =
α10
d10
and γ3 =
α2
d2
.
4.3 Parameter estimation
Table 4.1 provides the description and values of all the parameters that appear in
model system (4.2.1). As noted in Chapter 3, most of the parameters are taken from
the literature, although not always from cancer experimental data.
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Table 4.1: Estimated Parameter values.
Parameter Description Values Units Source
α2 production rate of IL-2 due to CD4+ T cells 5 pg/cell day [5, 33]
α1 production rate of TGF-β due to cancers cells 7× 10−4 pg/cell day [5, 60]
α6 production rate of IL-6 due to cancers cells 7× 10−5 pg/cell day Estimated
α10 production rate of IL-10 due to M2 5× 10−4 pg/cell day [29, 30, 64]
α12 production rate of IL-12 due to M1 3× 1012 pg/cell day Estimated in[29]
d1 degradation rate of TGF-β 10 day−1 Estimated in [5]
d2 degradation rate of IL-2 10 day−1 [33, 51]
d6 degradation rate of IL-6 0.173 day−1 [40]
d10 degradation rate of IL-10 5 day−1 [29]
d12 degradation rate of IL-12 1.188 day−1 [29, 45]
s1 influx rate of M1 8000 cells/ml day Estimated
s2 influx rate of M2 800 cells/ml day Estimated
s3 production of CD4+ T cells by the sources 10000 cells/ml day Estimated
k1 per capita death rate of M1 0.02 day−1 [29]
k2 per capita death rate of M2 8× 10−3 day−1 [29, 31]
λ1 transformation rate of M1 by TGF-β 0.075 day−1 Estimated in [64]
λ2 transformation rate of M2 by IL-6 0.075 day−1 Estimated in [64]
ν transition rate from M2 to M1 5× 10−2 day−1 [57, 64]
β1 proliferation rate of T cells due to IL-12 106 cells/ml day [23]
β2 proliferation rate of T cells by IL-2 0.1245 pg/cell day [5, 33, 34]
β3 loss of cancer cells 10−5 ∼ 10−9 day−1 [39, 53, 63] and estimated (10−9)∗
K2 saturation constant of proliferation by IL-2 2× 107 pg/ml [33, 34]
K10 saturation constant for anti-proliferation by
IL-10
2.5× 107 pg/ml [23]
µ1 per capita death rate of uninfected CD4+ T
cells
0.02 day−1 Estimated in [61]
µ2 infection rate of CD4+ T cells due to infiltra-
tion by free viruses
2.4× 10−8 ml/day Estimated in [61]
µ4 per capita death rate of CD8+ T cells 0.03 ∼ 0.0412 day−1 [33, 34]0.03∗
µv clearance rate (loss) of free viruses 2.4 day−1 Estimated in [61]
µ5 per capita death rate of infected CD4+ T cells 0.26 day−1 Estimated in [61]
δ2 lytic death rate of infected CD4+ T cells 0.24 day−1 Estimated in [61]
r cancer growth rate 0.18 ∼ 0.19 day−1 [5, 33, 34, 63] 0.19∗
C0 maximum cancer density 106 cells/ml Estimated in [39]
N number of virions released upon burst by an
infected T4 cell
1000 cells/ml [61] and assumed
ζr the measure of efficacy of reverse transcrip-
tase inhibitors(RTIs)
[0, 1]
ζp the measure of efficacy of protease in-
hibitors(PIs)
[0, 1]
PM1 , PM2 , PT4 , PTi4 , PT8 chemo-induced immune cell death rates 0.6 day
−1 [12, 35]
PC chemo-induced cancer cell death rate 0.9 day−1 [12, 35]
dD chemo drug elimination rate 0.9 day−1 [12, 35]
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4.4 Simulation results
4.4.1 Results with no chemotherapeutic drug
As in Chapter 3, the results presented below of the numerical simulations for sys-
tem (3.3.1) were obtained using Matlab ODE45 Solver which employs simultane-
ously the fourth and fifth order Runge Kutta schemes. Unless otherwise stated,
parameters are as stated in Table 4.1.
We take the following initial conditions: for instance, from steady state of equa-
tion (3.2.3), we get s2 = k2M2 and since k2 = 0.008/day, implying that, M2 =
100000cells/ml. Same applies for M1 and T4. We have; M1(0) = 400000 cells/ml,
M2(0) = 100000 cells/ml, T4(0) = 500000 cells/ml, Ti4(0) = 0 cells/ml, V(0) =
1000 copies/ml, T8(0) = 100 and C(0) = 100 cells/ml. We explore the effect of
combined HIV therapy on the cancer. Recall that one type of drugs (RTIs) reduces
the infection of T4 cells by virus by a factor 1− ζr, while another type of drugs (PIs)
reduces the proliferation rate of virus within infected T4 cells by a factor 1− ζp. We
say that RTI has efficacy of n% if ζr = n/100, and similarly PI has efficacy of n% if
ζp = n/100.
Figure 4.1 is a combination therapy map for cancer cells. Starting with C(0) =
100 cells/ml, it shows the density of cancer cells at days 350, 1000 and 20000 for
any combination of ζr and ζp. In particular, with no drugs, C(350) = 5.25× 104
cells/ml, C(1000) = 4.3× 105 and C(2000) = 8.54× 105.
We observe from our analysis that a dose of 90% effective RTI drugs with as low as
10% effective PI drugs will reduce the state of the cancer and same applies for 90%
effective PI drugs. Therefore, to achieve the best outcome, one of the drug efficacy
should be approximately 90% and above or both drugs should be approximately
80% effective. From the convex shape of the equi-cancer-cell-number curves we see
that if two drugs, ζr with efficacy n% and ζp with efficacy m%, (n + m < 100) can
be replaced by just one drug, say ζr, with efficacy ζr = (n + m)% then the result
will lead to a decrease in the growth of the cancer.
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(c) Contour plot showing cancer cells density after 2000
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Figure 4.1: Combination therapy Map: C(t) as a function of RTIs (ζr) and PIs (ζp)
combination with the rest of parameters as defined in Table 3.3. The color bar shows
the C(t) values for various drug combination.
Figure 4.2 shows the reduction curves that represent the reduction of cancer load
after time, t = 350, 1000, 2000 days for various ζr = ζp anti-virus drugs combina-
tions. The cancer load is observed to reduce though mildly as the efficacy, ζr = ζp
gets larger as observed in Figure 4.1 as well. This implies that best outcome, i.e.
smaller cancer load will be achieved with the two drugs both of higher efficacies.
After 350 days, initiating treatment with anti-virus drugs leads to a smaller cancer
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Figure 4.2: Cancer reduction curves after various time, t with the rest of the param-
eters as in Table 3.3. The dots correspond to the cancer load at each anti-virus drug
combination, with ζr = ζp.
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Figure 4.3: Evolution of cancer cells in system (3.3.1) over 2000 days with the rest of
the parameters as defined in Table 3.3.
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load as compared to t = 1000 or t = 2000 days. This might explain why early treat-
ment of HIV would be preferred as it leads to reduction of the cancer density to a
lower state.
Figure 4.3 shows the dynamics of cancer cells with inclusion of varying efficacies
of the two drugs in the model. In Figure 4.3(a), we observe a slight decrease after
the 2000 days in the growth of the cancer cells given either ζr = 0.0 (ζp = 0.8)
and ζp = 0.8 (ζr = 0.0). However, given ζr = m, ζp = n, where n, m < 0.8,
and n + m = 0.8, combining the drugs will not effectively reduce the cancer load
and as discussed above from Figure 4.1 replacing the two drugs with one of higher
efficacy would lead to a significant decrease in the cancer growth. Figure 4.3(b),
shows varying the efficacies of the drugs such that we obtain 90% effective drug
combination. Similarly, given ζr = 0.0 (ζp = 0.9) and ζp = 0.9 (ζr = 0.0), we
observe the number density of cancer cells reducing to 7.137× 103 as seen in Figure
4.3(b).
Figure 4.4 is a color map of T cells at t=350, 100 and 2000 days as a function of ζr and
ζp. Similar to Figure 4.1, we see that if the two drugs with efficacies m% and n%
can be replaced by one drug with efficacy (n + m < 100) then the resulting number
of CD4+ T cells will increase. However, Figure 4.5 shows the T cells color map
without cancer in the host population. We observe an increase in number of T cells
to a higher level after 1000 days as compared to Figure 4.4.
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Figure 4.4: Combination therapy map: T4(t), for t=350, 1000 and 2000 days as a
function of RTI (ζr) and PI (ζp) combination, the parameters are as in Table 3.3. The
color bar shows the T4(t) values for various drug combination.
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Figure 4.5: Combination therapy map: T4(t), for t=1000 days with no cancer in the
host population as a function of RTI (ζr) and PI (ζp) combination, the parameters are
as in Table 3.3. The color bar shows the T4(t) values for various drug combination.
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Indeed, suppose we wish to maintain the CD4+ T cells population at level T4 =
500000cells/ml after 1000 days. We use Figure 4.6 to determine the pairs ζr, ζp for
which the corresponding equi-color curve indicates the level T4; we can write these
pair of points as ζp = h(ζr) where h is a monotone decreasing function. Next, for
each pair ζr, h(ζr) we depict from Figure 4.4 the corresponding value of C(1000),
and denote it by C(ζr). As we vary ζr over the range of all possible efficacy levels,
say a < ζr < b, for which ζr = h(ζr) is also a realizable efficacy level, we obtain
a range of values C(ζr). Figure 4.6 shows a typical curve C = C(ζr); we see that
the smallest number of cancer cells occurs at one of the extreme points, i.e at ζr = a
or ζr = b. Thus, the best strategy is to choose the minimum or maximum level of
efficacy for ζr and the corresponding ζp by ζp = h(ζr).
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Figure 4.6: Cancer cell density curve, C(ζr) at t = 1000 days, for each pair (ζr, h(ζr)),
the parameters are as in Table 3.3.
Considering Figure 4.7, we analyse the effect of inclusion and exclusion of HAART
therapy on the dynamics of T4 cells with no cancer in the host immune system.
Note that the T4 cell count in this case is cells per ml. Figure 4.7(a) shows the profile
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of CD4+ T cells over a period of 2000 days with no cancer in the host population,
where we observe that the cells count increase then eventually decrease to a steady
state of approximately 1.2× 105 cells/ml (120 cells/mm3) and remain in that state
for the rest of the time. We also observe from Figure 4.7(b), where treatment of HIV
is initiated with the two drugs each of efficacy, 50%, i.e ζr + ζp = 1 an increase in
the number of T4 cells followed by a decrease that eventually stabilizes at approx-
imately 5.0 × 105 cells/ml (500 cells/mm3). Similar results to Figure 4.7(b) hold
when the efficacies of the drugs are not the same i.e ζr 6= ζp (but ζr + ζp = 1) except
for either ζr > 0.8 or ζp > 0.8, where we observe the steady state stabilizing at ap-
proximately 1.3× 106 cells/ml (1300 cells/mm3) see Figure 4.8(b). This imply that
for the T4 cells count to stabilize at approximately 500 cells/mm3, the efficacies of
the drugs administered to the patients should be m + n = 100% with m, n < 80%.
Similar results are observed with cancer in the population.
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Figure 4.7: Population dynamics of T helper cells (cells/ml) over a period of 2000
days for the case of no cancer in the host immune system, i.e C = 0. The rest of the
parameters as defined in Table 3.3. The inset plots show the T helper cells dynamics
over 20 days.
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Figure 4.8: Population dynamics of T helper cells (cells/ml) with cancer in the host
immune system over 2000 days with the rest of the parameters as defined in Table
3.3. The inset plots show the T helper cells dynamics over 20 days.
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4.4.2 Results with chemotherapeutic drug
Considering the parameter associated with chemotherapy intervention, uin(t), we
assume administration of 2.3869 mg/L ' 2386900 pg/mL per every 21 days for
cancer cells, as suggested in [12]. Therefore, if T (every 21 days) is the drug infusion
time, then the mass inflow is given by
uin =
{
2.3869, t = T = 21n, n = 1, 2, ...
0, otherwise
The drug administration pattern is depicted in Figure 4.9.
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Figure 4.9: Chemotherapeutic drug dose concentration in the system administered
1 day every 21 days for 200 days i.e 9 doses every 21 days.
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Figure 4.10: Population dynamics for a period of 200 days of the cancer cells in
model system (4.2.1) with both therapies (HAART and chemotherapy) with param-
eters as in Table (3.3). Initial conditions: M1(0) = 2000 cells/ml, M2(0) = 2500
cells/ml, T4(0) = 3 × 105 cells/ml, Ti4(0) = 1 × 103 cells/ml, V(0) = 4 × 103
copies/mL, T8(0) = 3000 cells/ml .
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With the inclusion of chemotherapy in the model, no difference is seen for the cases
with and without HAART therapy. Chemotherapy administration occurs when
the cancer cells are detectable, thus considering the initial state of the cancer as
1× 105cells/ml, we observe that the drug is very effective in eliminating the cancer
cells when the decay rate in the system is smaller. Administering same therapy but
with a higher decay rate in the system, the cancer will not be eliminated and instead
the cancer will regrow as seen in Figure 4.10a. This implies that the length of time a
chemotherapeutic drug has to act against the cancer is very critical since smaller de-
cay/elimination rate implies a longer time required to act against the cancer. Figure
4.10b thus shows the effect of smaller decay rate on cancer elimination.
4.5 Conclusion
In this chapter we investigated the effect of HIV treatment and chemotherapy in
the AIDS-related non-Hodgkin Lymphoma. We extended the model developed in
Chapter 3 to include the chemotherapeutic intervention terms.
We investigated the effect of combined RTI and PI drugs on reduction of cancer
load. We created a combination therapy map for cancer-cells number: C(t) for
t=350, 1000 and 2000 days as a function of ζr and ζp combination. The results clearly
show the best combination of the two drugs that reduces the cancer load in the host
environment while maintaining the CD4+ T cells at an ’acceptable’ level.
The use of either of the drugs would be effective if the efficacy is approximately 90%
and above which might not be plausible. For an effective suppression of the cancer
cells growth, an optimal combination of PIs and RTIs presents the best treatment
option, with the right efficacies as seen in our results. We can therefore, conclude
from our model that using moderate efficacy from different classes of the HAART
regimen can be as good as using a high efficacy therapy from a single drug.
However, despite patient’s strong immune response and treatment of the HIV with
the reverse transcriptase inhibitors (RTIs) and protease inhibitors (PIs) drugs of
higher efficacy for instance, 80% efficacy, complete elimination of the cancer by the
immune system is actually not possible unless the cancer elimination rate is very
high i.e very strong immune response and thus early initiation of treatment might
help reduce the cancer load in the system as in our results. It might also explain
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why late initiation of treatment is not very helpful to NHL patients.
Our results might also give an insight on the approximate efficacies of the HAART
regimen used in the treatment of HIV for instance, the PIs and RTIs. From the
results we can deduce that the efficacies of each of the drug in HAART regimen
given to HIV patients are approximately less than 80% since initiation of treatment
with drugs of the said efficacies result in steady state of approximately 500 cells
mm−3 to 800 cells mm−3 as the case mostly observed in HIV patients under highly
active antiretroviral therapy.
In the case of chemotherapy intervention, the time taken by the drug to act on
the cancer is an important factor and thus to reduce cancer related deaths, the
chemotherapeutic drugs used should have low elimination rates. This implies that
the absorption, distribution and clearance of the drugs take much longer time and
this might explain why a few of these drugs are more effective when given at a slow
continuous rate for a few days at a time.
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Discussions
In this dissertation, we have formulated a deterministic model showing the dy-
namics of HIV-related non-Hodgkin’s lymphoma (NHL). Firstly, we analysed a
HIV-related NHL with HIV treatment and later extended the model to include
chemotherapeutic intervention.
The first model presented in Chapter 3, described the dynamics of HIV-related NHL
with inclusion of HIV treatment. The model comprised immune cells population,
cancer cells (NHL), cytokine population and lastly the free virus population. The
proof that the state variables were positive and bounded was carried out to ensure
that the region which the model is analysed is biologically feasible. The main aim
here was to investigate the existence of steady states and analyse their stability by
carrying out bifurcation analysis. Mathematical analysis in this chapter indicates
existence of cancer-free steady states and existence of endemic (cancer-persistence)
steady state. Sensitivity analysis on the parameters was carried out to establish the
parameters that play a significant role in the dynamics of the cancer. Numerical
simulations were then carried out to enhance the understanding of the theoretical
results. Our numerical results indicate the existence of multiple equilibria with re-
spect to different range of values for cancer elimination rate, the parameter respon-
sible for immune response. This implies that the cancer elimination rate plays a
crucial role in defining the cancer behaviour. Bifurcation analysis of this parameter,
shows the immune response is crucial in suppressing the cancer growth and is only
effective if it falls within a specific window of opportunity to effectively suppress
the cancer growth. The results also indicate that despite initiation of HIV treat-
63
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ment with the combined therapy, unless the HIV infection rate is low, no significant
reduction in the cancer cell count would be realised.
In Chapter 4, we extended the model to incorporate chemotherapy treatment. Our
main interest here was to explore the effect of combined HIV therapy on the cancer
cell density and the effects of chemotherapy on the cancer growth. We determined
how to optimally choose the proportions of RTI and PI in the anti HIV combination
drug HAART in order to maintain an acceptable level of CD4+ T cells and, at the
same time, to reduce cancer growth as much as possible. Our numerical results
might give an insight on the approximate efficacies of the HAART regimen used in
the treatment of HIV for instance, the PIs and RTIs. Our results also show that, for
an effective suppression of the cancer cell growth, combination of PIs and RTIs is
the best treatment to employ with the right efficacies as discussed in Chapter 4 in
order to reduce the cancer growth as much as possible.
The study by Hoffman et al. [26], indicated that most of the NHL diagnosis occur
when CD4 T cell count is less than 350 cells mm−3 and/or is less than 200 cells
mm−3. Our analysis was done with the T cells at steady states implying low CD4
T cell count and therefore, the predictions from our model results would be useful
since most of the patients commence their HAART dosage when the count is less
than 350 cells mm−3 and thus the appropriate combination would be better when
initiated immediately after the diagnosis. Stebbing et al.[56] analysed the proba-
bility of developing NHL after initiation of HAART and deduced that combined
antiretroviral regimen that is, PIs and RTIs when administered reduce the risk of
developing NHL. In our study however, we have analysed and discussed the right
combination of these two drugs that would reduce the cancer load to a manageable
level when initiated at the right time in HIV-NHL patient.
We further investigated the effect of chemotherapy on the dynamics of the tumor
and the numerical results pertaining to chemotherapeutic drugs might explain why
a few of these drugs are more effective when given at a slow continuous rate. The
results also explain why late initiation of HIV treatment might not be helpful to
NHL patients.
The model presented in this thesis is a very simplified caricature of a complex bio-
logical interaction of immune cells, cytokines and HIV (with the inclusion of com-
bination antiretroviral therapy treatment) in a cancer environment and therefore it
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has some lucid limitations. The model does not take into account the spatial growth
of the cancer and the associated metabolic elements and pathways. There is also
paucity of experimental data for model verification. Despite these limitations, the
model results have significant bearings on NHL dynamics and its coexistence with
HIV. Our model provides a unique opportunity to influence policy on HIV related
cancer treatment and management.
The model presented in this thesis is a very simplified description of a complex
biological interaction of immune cells, cytokines and HIV (with the inclusion of
combination antiretroviral therapy treatment) in a cancer microenvironment and
therefore it has some lucid limitations. There is also paucity of experimental data
for model verification. Despite these limitations, the model results have significant
bearings on NHL dynamics with the inclusion of combined HIV treatment that
might provide a unique opportunity to influence policy on NHL treatment and
management.
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Modelling the dynamics of HIV-related non-Hodgkin
lymphomas in the presence of HIV treatment and
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Abstract
Non-Hodgkin lymphomas (NHLs) and HIV co-existence both in vivo and in vitro in a
tumor-immune environment has been studied to a large extent. Most of the studies have
suggested that specific cytokines produced by the immune system cells and the tumor play
an important role in the dynamics of NHLs. In this paper, a mathematical model describing
the NHL-immune system interaction in the presence of the Human Immunodeficiency Virus
(HIV), HIV treatment and chemotherapy is developed. The formulated model, described
by non-linear ODEs shows existence of multiple equilibria whose stability and bifurcation
analysis are presented. From the bifurcation analysis, bistability regions are evident. We
observe that with and without HIV treatment, the system results in a non-aggressive tumor
size or aggressive tumor (full-blown tumor) depending on the initial conditions. The results
further suggest that at a low endemic state, patients can live for longer period of time with the
tumor which might explain why some patients can live with cancer for many years. However,
initiation of HIV treatment in patients with NHL is observed to lower these endemic states
of the tumor. Our results explain why late initiation of HIV treatment might not be helpful
to NHL patients. We further investigated the effect of chemotherapy on the dynamics of
the tumor. Our simulation results might explain why a few of these chemotherapeutic drugs
are more effective when given at a slow continuous rate. The model provides a unique
opportunity to influence policy on HIV related cancer treatment and management.
Keywords: NHL; cytokines; modelling; simulation; bifurcation; HIV; chemotherapy.
1 Introduction
The greatest risk factor for the development of NHLs is immune deficiency often caused by
the Human immunodeficiency virus (HIV) [38]. Patients with HIV infection develop lymphoma
(cancers of the lymphocytes/immune system) about 100 times more often and Kaposis sarcoma
about 400 times more often than non-infected individuals [1, 38]. AIDS-related non-Hodgkin’s
lymphomas (AIDS-NHLs) are the second most frequent cancer in the wake of Kaposi’s sarcoma
associated with AIDS, and are the cause of death in approximately 16% of HIV-infected indi-
viduals [8,14,20]. NHLs are consistently derived from B-cells and are characterized by extreme
aggressiveness. Non-Hodgkin’s lymphoma, is a heterogeneous group of malignancies involving
a controlled clonal expansion of transformed B cells [11,17]. Untreated HIV infection as widely
∗Corresponding author: Email: rosemary@aims.ac.za
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discussed, causes reduction in the number of T cells and hence more B cells are made. When
the latter occurs too fast, there are increased chances that they develop into NHL which are
classified viz.: AIDS-related Burkitt’s lymphoma (AIDS-BL), AIDS-related diffuse large cell
lymphoma (AIDS-DLCL) and AIDS-related primary effusion lymphoma (AIDS-PEL) [7].
Immune response to tumor growth exist in tumor-bearing hosts. Tumors often induce dysfucn-
tion in the response mechanisms by impairing the regulatory networks driven by cytokines. The
role of cytokines in the pathogenesis and management of AIDS-NHL has been studied exten-
sively see for instance [5,7,11]. Cytokines are regulatory molecules that are secreted by various
cell types for the regulation of immune response to infection. The ones that play a crucial role
in the pathological processes of tumors are classified as interleukins (ILs), tumor necrosis factors
(TNFs), transforming growth factors (TGFs), interferons (IFNs) and colony-stimulating factors
(CSFs) [13]. Cytokines influence the biology of tumors either by promoting tumor growth or
impairing antitumor responses [5]. There is a disruption of normal cytokine regulatory net-
works in the presence of immune suppression [18]. Research into the cytokines expressed in
AIDS- related lymphomas has shown elevated serum levels of IL-6 and IL-10 in HIV infected
individuals [5, 7, 19].
With regards to the functions of the cytokines expressed in patients with NHL, TGF-β acts as a
negative growth regulator of the lymphoma-derived cell line and has been shown to be potentially,
an inhibitory factor in the regulatory network of AIDS-related lymphomagenesis [3,20]. It has an
immunosuppressive role, mediated predominantly by its effects on T cells and antigen-presenting
cells (APCs) [6], thus favouring the growth of malignancies. As indicated by [40], TGF-β
is likely to contribute to the deficit in T-cell surveillance which is of paramount importance
in suppressing tumor growth. Anti-tumor activities by the human body often involves the
secretion of interleukin (IL)-12 which enhances natural killer cell activities [25] by activation
of CD8 effector cells and the induction of interferon γ (IFN-γ) an essential cytokine in tumor
regression [23]. It has also been shown that IL-12 induces IL-10 production as a negative feedback
for IL-12-induced immune response [23,24].
Interleukin 2 (IL-2) is a cytokine signaling molecule in the immune system produced mainly by
the CD4 T-cells and is responsible for the growth, proliferation, and differentiation of CD4+ T
cells, to become cytotoxic or CD8+ T cells (CTLs). The CD8+ T cells (adaptive immune system)
are specialised for lytic function and therefore believed to be the main effector cells [39]. The
CD8 effector cells are also responsible for lysis of the HIV infected CD4 T-cells [37, 43] and the
production of chemokines which inhibit the infection of the macrophages by the virus [28]. The
in vivo and in vitro experimental findings in [30] on the production of IL-10, IL-6, TNF-α and
IL-2 cytokines in the tumor sites of NHL patients showed a correlation between the cytokines.
IL-6 has been identified as a key cytokine for the B-cell NHLs’ growth and survival [26].
Human tumors contain macrophages which are often phenotipically classified as M1 and M2
[9, 12]. M1 are the macrophages that have undergone cell activation in response to interferon
(IFN) while the M2 are those that have undergone activation in response to IL-4. The activated
macrophages (M1) are associated with acute inflammation and T-cell immunity and the immune
suppressive macrophages (M2) are associated with active promotion of tumor growth and thus
are mainly the tumor associated macrophages (TAMs) [9, 12]. The M1 phenotype is character-
ized by the expression of high levels of pro-inflammatory cytokines, and M2 macrophages are
considered to be involved in tumor progression and to have immunoregulatory functions [2,22].
TAMs can switch type between pro-inflammatory M1 and anti-inflammatory M2 in the tumor
environment [12]. IL-6 and TGF-β induce M2 polarization and promote an immunosuppressive
environment [26]. One of the most important features of M1 macrophages is the production of a
2
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T-cell stimulating cytokine IL-12 while the M2 macrophages are linked to the profuse production
of IL-10, which down regulates the activities of IL-12 [24]. The IL-10 cytokines also have some
direct inhibitory effects on the CD4+ T cells in that they inhibit proliferation and the cytokine
synthesis, however, on CD8+ T cells research has shown indirect inhibitory effect by IL-10 [27].
Infection by the Human immunodeficiency virus (HIV), is typified by a marked deficiency of
CD4+ T cells and a persistent stimulation of B cells [10], leading to increased NHL risk in
people with HIV/AIDS. More than 90% of HIV-associated NHLs are derived from B cells, and
the majority are high-grade and extranodal [10]. In this study, the depletion of these cells is very
vital since it allows for an immunosuppressive environment that reduces the clearance rate of the
tumor cells by the killer CD8+ T-cells of the host immune system. Highly active antiretroviral
therapy (HAART) and chemotherapeutic drugs are two of the main therapeutic measures that
have long been used to curb HIV infection and cancer growth respectively. We therefore consider
the treatment of HIV with highly active retroviral therapy (HAART) by reverse transcriptase
inhibitors (RTIs) and protease inhibitors (PIs). In addition, we also include chemotherapy which
is a drug administered to kill the tumor cell due to their mode of action i.e killing cells that
divide more rapidly, a feature associated with tumor cells. These drugs though targeted at the
tumor cells, can also be destructive to other cells in the host immune system. Our study is
motivated by the work in [16], where combination of cytokines were incorporated in modelling
pancreatic cancer. We will therefore, consider a combination of cytokines in modelling the role of
HIV in the NHL growth with and without the two drug interventions. In our study, we consider
the macrophages (pro-inflammatory M1 and anti-inflammatory M2), T cells (healthy CD4
+
T cells, HIV-infected CD4+ T cells and CD8+ T cells), the virus and cancer cells. The cells
interact with each other through a conglomerate of cytokines. We will focus on the stability and
bifurcation analysis to establish the existence of the equilibria and to understand the behaviour
of the formulated model. Moreover, most of the research has always focused on modelling either
tumor dynamics in a host immune system, HIV dynamics or the interaction of the tumor cells
with the immune system in the presence of HIV in vivo [29,32,38]. However, most importantly,
none of these studies to the best of our knowledge have incorporated all the cytokines present
in the host immune system in an HIV and tumor co-infection scenario.
The paper is organized thereinafter as follows : The formulation and analysis of the HIV-related
non-Hodgkin lymphoma model with the inclusion of the two therapies i.e. chemotherapy and
HAART are presented in Section 2. In Section 3, numerical simulations for the model and
parameter estimation are carried out to illustrate the stability and bifurcation results as well as
the effect of the two therapies on cancer evolution. We then discuss our conclusions in Section
4.
2 Methods
We postulate a mathematical model driven by the following variables: tumor associated macrophages
(pro-inflammatory M1 and anti-inflammatory M2), T cells ( healthy CD4
+ T cells, infected
CD4+ T cells, and CD8+ T cells), HIV virus, V and the cancer cells, C.
The postulated interactions described in Section 1 are depicted in Figure 1.
Table 1 shows the variables considered in our mathematical model and the parameters used in
formulating our model equations are summarised in Table 2.
3
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
NHL
 C
CD8+ 
   T
8
 
     
IL-2
  I
2
CD4+
    T
4
   
Infected 
CD4+  T
4
i
IL-12
  I
12
IL-10
  I
10
 
IL-6
 I
6
TGF-β
   Tβ
HIV
 V
 
M
1
 M
2
T cells
Cytokines
Macrophages
Figure 1: Transmission dynamics of HIV-related NH Lymphomas. We have macrophages
M1,M2, T-cells (immune cells) T4, T
i
4, T8, cytokines (Tβ, I6, I10, I12, I2), the tumor cell, C and
HIV, V . The pool of viruses V , through infection, influence the movement of the CD4+ T cells
into the infected compartment T i4. We have used dotted lines with arrow heads to represent
cytokine production, cell activation and viruses release. The bold lines represents induction of
the CD8+ memory by CD4+ T-cells and activation of CD4+ T-cells due to M1 as well as the
inflow of the infected T i4 from T4 compartment. Similarly, the bold lines represent transition of
the macrophages. The inhibition are represented by the square heads lines where IL-10 hinders
the proliferation and activation of both CD4+ and CD8+ T-cells and the killer cell (CD8+)
reduces the growth of the tumor by increasing its apoptosis.
2.1 Model Equations
We now present the model equations by considering cytokines dynamics and the cells dynamics.
The parameters are assumed to be non-negative.
2.1.1 Cytokine dynamics
In model system (1), the ordinary differential equations track the dynamics of the cytokines,
where the positive terms show the secretion of the cytokines by respective cells into the tumor
environment while the negative terms indicate the natural decay of the cytokines which occurs
in a short time-scale as opposed to the dynamics of the cell population. The secretion and
4
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
State Variable Descrption Units
M1 density of pro-inflammatory tumor associated macrophages cells/ml
M2 density of anti-inflammatory tumor associated macrophages cells/ml
T4 density of healthy CD4
+ T cells cells/ml
T i4 density of virus-infected CD4
+ T cells cells/ml
V density of HIV virus/ml
T8 density of CD8
+ T cells cells/ml
C density of cancer cells cells/ml
Tβ concentration of transforming growth factor (TGF-β) pg/ml
I6 concentration of interleukin 6 (IL-6) pg/ml
I10 concentration of interleukin 10 (IL-10) pg/ml
I12 concentration of interleukin 12 (IL-12) pg/ml
I2 concentration of interleukin 2 (IL-2) pg/ml
Table 1: State variables and their units
decay of the cytokines are assumed to occur at constant rates. This assumption follows directly
from [16].
dTβ
dt
= α1C − d1Tβ dI6
dt
= α6C − d6I6,
dI10
dt
= α10M2 − d10I10, dI12
dt
= α12M1 − d12I12,
dI2
dt
= α2T4 − d2I2,

(1)
where parameters, α1 and α6 represent the production rates of Tβ and I6 by the cancer cell,
d1 and d6 their respective decay rates. I12 and I10 are produced primarily by M1 and M2
respectively at the rates α12 and α10. These two cytokines decay at the rates d12 and d10
respectively. Lastly, α2 represents the production rate of I2 by healthy T4 cells and they decay
at the rate d2.
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2.1.2 State variables equations
dM1
dt
= s1 − k1M1 + νM2 − (λ1Tβ + λ2I6)M1 − PM1(1− e−D)M1,
dM2
dt
= s2 + (λ1Tβ + λ2I6)M1 − k2M2 − νM2 − PM2(1− e−D)M2,
dT4
dt
= s3 + β1
I12M1
K10 + I10
+ β2
I2T4
K2 + I2
− µ1T4 − (1− ζr)µ2V T4 − PT4(1− e−D)T4,
dT i4
dt
= (1− ζr)µ2V T4 − µ5T i4 − PT i4(1− e
−D)T i4,
dT8
dt
= β1
I12
K10 + I10
+ β2
I2T8
K2 + I2
− µ4T8 − PT8(1− e−D)T8,
dV
dt
= (1− ζp)Nδ2T i4 − µvV,
dC
dt
= rC
3
4
(
1−
(
C
C0
) 1
4
)
− β3CT8 − PC(1− e−D)C,
dD
dt
= uin(t)− dDD

(2)
In system (2), the influx of the macrophages M1 and M2 due to the attraction to the tumor site
are represented by s1 and s2 respectively. The switching of macrophages from M1 to M2 and
vice versa is captured in the terms (λ1Tα + λ2I6)M1 and νM2 respectively, where the former is
activated by cytokines TGF-β and IL-6. However, the transformation from M2 to M1 is assumed
to be unbiased and occurs at a constant rate ν. The natural deaths of the macrophages M1 and
M2 are assumed to be directly proportional to the concentration rate of the macrophages thus
occurs at the rates k1 and k2 respectively.
The third equation of system (2) describes the dynamics of the healthy CD4+ T cells. The
recruitment of the healthy CD4+ T cells is s3, from a source such as the thymus and their
activation which is enhanced by IL-12 [16,44] occurs at a rate β1. The MHC-II molecule together
with IL-12 activates the naive T helper cells, where the former also aid in the priming of the
naive T helper cells into effector T cells and memory T cells. This process is hindered by IL-10.
Proliferation due to IL-2 occurs at a rate β2. We thus have the terms β1I12M1/(K10 + I10) and
β2I2T4/(K2 + I2) since we assume saturation in proliferation of the CD4
+ T cells. The natural
decay rate of CD4+ T cells is µ1. Assuming that upon infection of the cells with the HIV viral
particles at a rate µ2, all the healthy cells become productively infected and therefore, we ignore
the latent stage of the infected cells which is captured in various models for instance the model
discussed in [29]. Since RTI drugs affect the free virus-cell transmission, we thus have the term
(1− ζr)µ2V T4, is the rate of reduction in the number of infected cells, with parameter ζr ∈ [0, 1]
as a measure of efficacy of RTIs. If ζr = 1, then the RTIs offer 100% protection while if ζr = 0,
zero protection is offered.
For the infected CD4+ T cells, the per capita death rate µ5, is assumed to include both natural
death and the bursting. The rate at which the infected cells burst and produce viruses is δ2. We
can safely assume that µ5 > δ2. Since the productively infected cells is assumed to produce N
virions during its lifetime, the average virion production rate by infected cells is therefore given
by Nδ2. The role of PIs, is captured in the term, (1 − ζp)Nδ2T i4, where (1 − ζp) measures the
reduction in the number of mature viruses produced, with ζp ∈ [0, 1], the efficacy of PIs. The
loss of virions due to clearance occurs at a constant rate µv. Similar conclusions can be drawn
for ζp = 0 and ζp = 1 as done for ζr.
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The dynamics of CD8+ T cells mirrors the dynamics of CD4+ T cells but with no source term.
The proliferation of the effector T cells (CD8+ T cells) only occurs due to IL-12 produced by
M1 and the process is hindered by IL-10 and is modelled by the terms β1I12/(K10 + I10) and
β2I2T8/(K2 + I2). However, the  included in the first term is a modification parameter which
represents the proliferation potential of CD8+ T cells when compared to that of CD4+ T cells
when influenced by IL-12 and IL-10. The loss of the cells is at a a per capita rate µ4.
Following [16], we assume the dynamics of the tumor is governed by two processes: i.e. intrinsic
growth of the tumor cells and the elimination due to the cytotoxic effector cells. Therefore,
considering the equation describing the tumor dynamics, the first term rC
3
4
(
1− (C/C0)
1
4
)
models the growth of the tumor which we assume as most of the living organisms, follows
universal law with r being the growth rate, C0, the maximum size of the tumor cell and the
total body mass of the tumor cell is represented by C. For greater elucidation on the growth
term, see [16, 45]. The clearance rate of the tumor cells occurs at a rate β3 and follows the
mass-action law.
Lastly, following [47, 48], most of the chemotherapeutic drugs are only effective during certain
phases of cell cycle (cell cycle specific) and pharmacokinetics indicate that the effectiveness of
the chemotherapeutic drugs is bounded. We therefore have the term (1 − e−D), a saturation
term representing the fraction of the cell killed by a dose, D of chemotherapy. This prompts the
inclusion the cell dose-response term
QDi = Pi(1− e−D)i for i = M1,M2, T4, T i4, T8, C.
Since the drug concentration in the bloodstream changes with time due to the processes involved,
i.e absorption, distribution, metabolism and excretion, we include an equation that tracks that
dynamics. Therefore, the terms in the non-homogeneous equation, dD/dt of system (3) reflects
the rate of change in the dosage concentration over a given period of time. uin(t) is a func-
tion of time that describes the amount of drug influx into the system and the injection time
assuming intravenous administration whereas dD represents the dug elimination rate. The drug
concentration equation assumes instantaneous distribution of the drug into all body parts.
2.2 Model Analysis
We assume quasi-steady-state approximation for the cytokines concentration since in our model
system the dynamics occur at different time scales. The dynamics of the cytokines ,that is,
their secretion and decay happen in a shorter time-scale when compared to that of the cells or
virus and thus we assume they reach their equilibrium almost instantaneously, see also [16]. We
therefore have, from model system (1) the following relations:
Tβ =
α1
d1
C, I6 =
α6
d6
C, I10 =
α10
d10
M2, I12 =
α12
d12
M1, I2 =
α2
d2
T4.
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Substituting the cytokine steady-states into equations in system (2), we obtain
dM1
dt
= s1 − k1M1 + νM2 − γcCM1 − PM1(1− e−D)M1,
dM2
dt
= s2 + γcCM1 − k2M2 − νM2 − PM2(1− e−D)M2,
dT4
dt
= s3 +
γ1M1M1
K10 + γ2M2
+ β2
γ3T4T4
K2 + γ3T4
− µ1T4 − (1− ζr)µ2V T4 − PT4(1− e−D)T4,
dT i4
dt
= (1− ζr)µ2V T4 − µ5T i4 − PT i4(1− e
−D)T i4,
dT8
dt
= 
γ1M1
K10 + γ2M2
+ β2
γ3T4T8
K2 + γ3T4
− µ4T8 − PT8(1− e−D)T8,
dV
dt
= (1− ζp)Nδ2T i4 − µvV,
dC
dt
= rC
3
4
(
1−
(
C
C0
) 1
4
)
− β3CT8 − PC(1− e−D)C,
dD
dt
= uin(t)− dDD

(3)
where γc = λ1
α1
d1
+ λ2
α6
d6
, γ1 = β1
α12
d12
, γ2 =
α10
d10
and γ3 =
α2
d2
, with the general initial conditions
M1 ≥ 0,M2 ≥ 0, T4 ≥ 0, T i4 ≥ 0, V ≥ 0, T8 ≥ 0 and C ≥ 0
The model system (3) above represents the dynamics of the cell population and the HIV virus
in the presence of cytokines in a tumor environment, HIV treatment and chemotherapy. The
analysis of system (3) is therefore central in this study. We state two important model properties
of model system (3) before embarking on steady-state analysis. Our initial considerations focus
only the model with HAART and with no chemotherapy treatment. Therefore, we exclude the
equation tracking the concentration of the chemotherapy drug in the host system and the terms
representing the effects of chemotherapy on the immune cells and cancer cells in the subsequent
analysis.
2.2.1 Model Properties
Positivity of the solutions
Lemma 1. Given the initial conditions M1 ≥ 0,M2 ≥ 0, T4 ≥ 0, T i4 ≥ 0, V ≥ 0, T8 ≥ 0 and
C ≥ 0, then the solutions of M1(t),M2(t), T4(t), T i4(t), V (t), T8(t) and C(t) remain positive for
all t ≥ 0
Proof. Suppose t˜ = sup
{
t > 0 : M1 ≥ 0,M2 ≥ 0, T4 ≥ 0, T i4 ≥ 0, V ≥ 0, T8 ≥ 0, C ≥ 0
} ∈ [0, t],
implying t˜ ≥ 0. The first equation of system (3) gives
dM1
dt
≥ s1 − k1M1 − γ(t)M1, where γcC = γ(t).
8
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
Integration, yields
M1(t˜) ≥M1(0)e−[k1t+
∫ t
0 γ(s)ds] + e−[k1t+
∫ t
0 γ(s)ds]
∫ t˜
0
s1e
[k1t+
∫ t
0 γ(s)ds] ≥ 0.
Hence M1 is always positive for all t˜ > 0. Similarly
M2(t˜) ≥M2(0)e(−(k2+ν)t) + e(−(k2+ν)t)
∫ t˜
0
s2e
(k2+ν)t ≥ 0.
Considering the CD4 T cells we have
dT4
dt
≥ s3 −Θ(t)T4, where Θ(t) = µ1 + (1− ζr)µ2V.
The solution of the differential equation is
T4(t˜) ≥ T4(0) exp
[
−
∫ t
0
Θ(s)ds
]
+ exp
[
−
∫ t
0
Θ(s)ds
](∫ t˜
0
s3 exp
[∫ t
0
Θ(s)ds
])
≥ 0.
Similarly we have
T i4(t˜) ≥ T i4(0) exp (−µ5t) ≥ 0.
Also
T8(t˜) ≥ T8(0) exp
[
−
(
µ4t−
∫ t
0
Φ(s)ds
)]
≥ 0, where Φ(t) = β2 γ3T4
K2 + γ3T4
.
Hence T4(t˜), T
i
4(t˜) and T8(t˜) are positive for all t˜ > 0. For the virus population we have
dV
dt
≥ −µvV, ⇒ V (t) ≥ V (0) exp (−µvt) ≥ 0.
Lastly, for the tumor cell population, we have
⇒ C(t˜) ≥ C(0) exp
[
−β3
∫
T8(s)ds
]
≥ 0.
Hence V (t˜) and C(t˜) are positive for all t˜ > 0. This implies that all the state variables are
non-negative and the solutions of our system remain positive for all t˜ ≥ 0.
Feasible Region
Lemma 2. The solution of our system with initial conditions M1 ≥ 0,M2 ≥ 0, T4 ≥ 0, T i4 ≥
0, V ≥ 0, T8 ≥ 0 and C ≥ 0 are contained (bounded) for all t ≥ 0 in the biologically feasible
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region defined by the set
Ω =
{
(M1,M2, T4, T
i
4, V, T8, C) ∈ R7+ : M ≤
(s1 + s2)
k
, T ≤ s3 +K
µ
, V ≤ Nδ2W
µv
,
C ≤
 rC 140
r − β3WC
1
4
0
4 ,
(4)
with M = M1 +M2 and T = T4 + T
i
4 + T8.
Proof. Summing the two macrophage populations from the first two equations of system (3) we
obtain
d
dt
(M1 +M2) =
dM
dt
≤ s1 + s2 − kM, for k = min {k1, k2} , (5)
The solution of (5) is
M(t) ≤ (s1 + s2)
k
+
(
M(0)− (s1 + s2)
k
)
e−kt.
When we take the limit supremum of M as t→∞, we have
lim
t→∞ supM(t) ≤
(s1 + s2)
k
= S.
This implies that
M1 ≤ S and M2 ≤ S.
Hence the macrophage population is bounded.
Again considering the sum of the T cell populations we have
dT
dt
≤ s3 + γ1S
2
K10 + γ2S
+ 
γ1S
K10 + γ2S
− µ1T4 − µ5T i4 − µ4T8,
≤ s3 + γ1S
K10 + γ2S
(S + )− µT, where µ = min {µ1, µ5, µ4} and M1,M2 ≤ (s1 + s2)
k
= S.
Through integration, we obtain
T (t) ≤ s3 +K
µ
+
(
T (0)− s3 +K
µ
)
e−µt, where K =
γ1S
K10 + γ2S
(S + ) .
Therefore
lim
t→∞ supT (t) ≤
s3 +K
µ
= W.
This implies that T4 ≤W, T i4 ≤W and T8 ≤W , hence each of the T-cell population is bounded.
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Considering the virus population we have
dV
dt
≤ (1− ζp)Nδ2W − µvV, since T i4 ≤W.
Integration gives
V (t) ≤ (1− ζp)Nδ2W
µv
+
(
V (0)− (1− ζp)Nδ2W
µv
)
e−µvt.
We also have
lim
t→∞ supV (t) ≤
(1− ζp)Nδ2W
µv
= Q.
Hence V (t) is thus bounded.
Lastly, we consider the tumor cell population. From the last equation in system (3), integration
of
dC
dt
≤ C
 r
C
1
4
− r
C
1
4
0
− β3W
 , since T8 ≤ s3 +K
µ
= W,
yields
C(t) ≤

rC
1
4
0 − exp
((
− (r−β3WC
1
4
0 )
4C
1
4
0
)
t
)
r − β3WC
1
4
0

4
.
So
lim
t→∞ supC(t) ≤
 rC 140
r − β3WC
1
4
0
4 = P.
Therefore C(t) is also bounded.
Our invariant region is therefore defined by Ω. The population will approach the thresholds
as t → ∞. We therefore deduce that the region Ω is positively invariant and attracting with
respect to model system (3). That completes the proof.
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2.2.2 Steady states
Setting the right hand side of system (3) to zero (without the terms representing the effects of
chemotherapeutic drug on the cells) we have
s1 − k1M∗1 + νM∗2 − γcC∗M∗1 = 0, (6)
s2 + γcC
∗M∗1 − k2M∗2 − νM∗2 = 0, (7)
s3 +
γ1M
∗
1M
∗
1
K10 + γ2M∗2
+ β2
γ3T
∗
4 T
∗
4
K2 + γ3T ∗4
− µ1T ∗4 − (1− ζr)µ2V ∗T ∗4 = 0, (8)
(1− ζr)µ2V ∗T ∗4 − µ5T i∗4 = 0, (9)
(1− ζp)Nδ2T i∗4 − µvV ∗ = 0, (10)

γ1M
∗
1
K10 + γ2M∗2
+ β2
γ3T
∗
4 T
∗
8
K2 + γ3T ∗4
− µ4T ∗8 = 0 (11)
rC∗
3
4
(
1−
(
C∗
C0
) 1
4
)
− β3C∗T ∗8 = 0. (12)
We start by solving for the steady states of M∗1 and M∗2 in equations (6) and (7) and we have
respectively
M∗1 =
σ1
Λ + σ2C∗
and M∗2 =
σ3 + σ4C
∗
Λ + σ2C∗
,
where σ1 = (ν + k2) s1 + νs2, Λ = k1 (ν + k2) , σ2 = k2γc, σ3 = k1s2, σ4 = (s1 + s2) γc.
We therefore assume a quasi steady-state for the viral population and thus from equation (10)
we have
V ∗ =
(1− ζp)Nδ2T i∗4
µv
.
Substituting V ∗ into equation (9) we obtain
T i∗4
(
(1− ζp)(1− ζr)µ2Nδ2T ∗4
µv
− µ5
)
= 0.
This gives
T i∗4 = 0 or T
∗
4 =
µvµ5
(1− ζp)(1− ζr)µ2Nδ2 .
From the above, it implies that T4 has one solution given by
T ∗4 =
µvµ5
(1− ζp)(1− ζr)µ2Nδ2 .
For T i∗4 = 0, our system at the steady state relates to HIV-free tumor equilibrium. Since our
objective is to investigate the role of HIV in the NHLs, we therefore analyse hereinafter the
steady state in which there is HIV in the system, that is, co-infection of HIV and the tumor in
the presence of HIV treatment.
We now solve for the steady states, E = (M∗1 ,M∗2 , T ∗4 , T i∗4 , V ∗, T ∗8 , C∗) where the state of the
tumor is also influenced by the presence of the HIV in the tumor environment. Firstly, we
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substitute T4 with the solutions T
∗
4 into equations (8) and (11). We notice that in the solution
T ∗4 , the number of virions, N, has an effect on the concentration of the CD4+ T cells in the
tumor environment, therefore the virus and the infected T cells play a crucial role in our model.
From (8) we solve for the solution of V at HIV-related NHL steady state denoted by V ∗ so that
V ∗ =
((
s3 +
T ∗24 β2γ3
K2+T ∗4 γ3
+
γ1σ21
K10(Λ+C∗σ2)2+(σ3+C∗σ4)(Λ+C∗σ2)
)
− µ1T ∗4
)
(1− ζr)µ2T ∗4
.
From V =
(1−ζp)Nδ2T i∗4
µv
we have
T i4
∗ = µv

((
s3 +
T ∗24 β2γ3
K2+T ∗4 γ3
+
γ1σ21
K10(Λ+C∗σ2)2+(σ3+C∗σ4)(Λ+C∗σ2)
)
− µ1T ∗4
)
(1− ζp)(1− ζr)µ2Nδ2T ∗4
 .
We then obtain the steady state T ∗8 as a function of C from equation (11). We have
T ∗8 =
γ1σ1 [(1− ζp)(1− ζr)µ2δ2NK2 + γ3µ5µv]
[(1− ζp)(1− ζr)µ2µ4δ2NK2 − γ3µ5(β2 − µ4)µv] [K10(Λ + C∗σ2) + γ2(σ3 + C∗σ4)] ,
Since β2 is the proliferation/activation rate of T8 due to IL-2 and µ4, the decay rate of T8, it
therefore suffice to assume that, for the existence of CD8+ T- cells, the proliferation rate must
always be greater than the death rate that is, β2 > µ4. Which implies that, the solution T
∗
8 is
positive if and only if
N >
γ3µ5µv(β2 − µ4)
(1− ζp)(1− ζr)µ2µ4δ2K2 = N
∗
crit
The existence of T ∗8 at endemic steady state is subject to N > N∗crit. Therefore, the viral particles
must exceed a certain threshold, N∗crit.
From equation (12) we have
g(C) = C
[
rC−1/4
(
1− (C /C0 ) 1/4
)
− β3T ∗8
]
= 0. (13)
The solutions of (13) are
C∗ = 0 or rC−1/4
(
1− (C /C0 ) 1/4
)
− β3T ∗8 = 0.
C∗ = 0 corresponds to a tumor free environment.
We define
g(C∗) = rC−1/4
(
1− (C /C0 ) 1/4
)
− β3T ∗8 = 0,
for the non-zero steady states.
Once the solutions of T8 are in terms of C, their substitution into the non-zero equilibria i.e
endemic equilibria result in an implicit function whose solutions can only be established numer-
ically. We begin by considering the tumor free steady state. The non-zero solutions of C are
subject to N > N∗crit.
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Tumor-free steady state
The tumor-free steady state, E0 exists and represents the state of HIV infection in the presence
of HIV treatment with no tumor cells in the host immune system. It reflects the possibility of
tumor development prevention by the immune system (i.e the tumors are not able to evade the
immune system. The state, E0 is therefore given given by
Tumor-free equilibrium, E0 = (M
∗
1 ,M
∗
2 , T
∗
4 , T
0∗
4 , V
∗, T ∗8 , C
∗), where
M∗1 =
σ1
Λ
, M∗2 =
σ3
Λ
, T ∗4 =
µvµ5
(1− ζp)(1− ζr)µ2Nδ2 , C
∗ = 0,
T i∗4 =
s3
µ5
+
β2γ3µ
2
vµ5
((1− ζr)(1− ζp)NK2µ22δ2 + γ3µ5µvµ2)((1− ζr)(1− ζp)Nδ2)
+
γ1σ
2
1
Λ2K10µ5 + Λγ2µ5σ3
− µ1µv
(1− ζr)(1− ζp)Nδ2µ2 ,
T ∗8 =
(γ1((1− ζp)(1− ζr)µ2δ2NK2 + γ3µ5µv)σ1)
((1− ζp)(1− ζr)µ2µ4δ2NK2 + γ3µ5(µ4 − β2)µv)(K10Λ + γ2σ3) ,
V ∗ =
(1− ζr)Nδ2s3
µvµ5
+
β2γ3µvµ5
(1− ζr)(1− ζp)2NK2µ22δ2 + γ3µ5µvµ2
+
Nδ2γ1σ
2
1
Λ2K10µvµ5 + Λγ2µvµ5σ3
− µ1
(1− ζp)µ2 ,
The existence of tumor-free equilibrium, E0 is subject to N¯crit < N , where N¯crit = max {Ncrit, N∗crit},
and
Ncrit =
µ5µvµ1
(1− ζp)(1− ζr)µ2δ2s3
N∗crit =
γ3µ5µv(β2 − µ4)
(1− ζp)(1− ζr)µ2µ4δ2K2 = Ncrit
γ3s3(β2 − µ4)
µ1µ4K2
The stability of this state is discussed in Section 3.
Tumor-persistence steady states
The steady-state analysis for the model discussed in this section (without the chemotherapy)
above clearly shows the existence of some feasible (non-negative) and non-zero tumor equilibria
(tumor-persistence steady states). However, due to mathematical intractability we are unable to
explicitly express the endemic states interms of the model parameters. We resort to numerical
simulations. To understand the effect of chemotherapy in the evolution of the cancer, we will
also perform numerical simulations in the following section.
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3 Numerical Simulations
3.1 Parameter Estimation.
Parameter values used in the numerical simulation are presented in Table 2 below where most
of the parameter values were obtained from different sources as indicated. Some of the param-
eters that do not have known values in the literature, were estimated to be close to the others
for instance, α6 was estimated to be close to α1. The initial conditions used in the numerical
simulations were set as follows; the initial value for the tumor density was set at 100 cells/ml
while the rest of the state variables used in our model the initial values were set at their quasi
steady-states. For instance, the patients are assumed to be in homeostasis, constant cell pop-
ulation/concentration. We note that the parameter N used in our simulation is 1000 virion
particles, though it varies as indicated in most of the studies, see for instance [29].
Table 2: Estimated Parameter values.
Parameter Description Values Units Source
α1 production rate of TGF-β due to cancers cells 7× 10−4 pg/cell day [34]
α2 production rate of IL-2 due to CD4
+ T cells 5 pg/cell day [32,42]
α6 production rate of IL-6 due to cancers cells 7× 10−7 pg/cell day Estimated
α10 production rate of IL-10 due to M2 5× 10−4 pg/cell day [34,36]
α12 production rate of IL-12 due to M1 3× 10−2 pg/cell day [36]
d1 degradation rate of TGF-β 10 day
−1 [42]
d2 degradation rate of IL-2 10 day
−1 [32]
d6 degradation rate of IL-6 0.173 day
−1 [?]
d10 degradation rate of IL-10 5 day
−1 [36]
d12 degradation rate of IL-12 1.188 day
−1 [36, 44]
s1 influx rate of M1 40 day
−1 [16, 36]
s2 influx rate of M2 20 day
−1 [16, 36]
s3 production of CD4
+ T cells by the sources 104 cells/ml day [29]
k1 per capita death rate of M1 0.02 day
−1 [36, 44]
k2 per capita death rate of M2 8× 10−3 day−1 [36]
λ1 transformation rate of M1 by TGF-β 0.075 ml/pg day [34]
λ2 transformation rate of M2 by IL-6 0.075 day
−1 [34]
ν transition rate from M2 to M1 5× 10−2 day−1 [34]
β1 activation rate of T cells by IL-12 10
6 cells/ ml day [44]
β2 proliferation rate of T cells by IL-2 0.1245 pg/cell day [32,42]
β3 loss of cancer cells 10
−7 day−1 [35](10−5) [16](10−7)
K2 saturation constant of proliferation by IL-2 2× 107 pg/ml [32]
K10 saturation constant for anti-proliferation by IL-10 2.5× 107 pg/ml [44]
 modification parameter 0.5 Estimated
µ1 per capita death rate of uninfected CD4
+ T cells 0.02 day−1 [29]
µ2 infection rate of CD4
+ T cells due to infiltration by
free viruses
2.4× 10−8 ml/ day [29]
µ3 infection rate of CD4
+ T cells due to direct contact
with infected T cells
2× 10−6 day−1 [46]
µ4 per capita death rate of CD8
+ T cells 0.03 day−1 [32]
µv clearance rate (loss) of free viruses 2.4 day
−1 [29]
µ5 per capita death rate of infected CD4
+ T cells 0.26 day−1 [29]
δ2 lytic death rate of infected CD4
+ T cells 0.24 day−1 [29]
δ3 elimination rate of infected CD4
+ T cells by CD8+
effector cells
0.78 day−1 [33]
N Virions produced during a lifetime by an infected
CD4+ T cells
Varies [29]
r cancer growth rate 0.19 day−1 [32, 35]
C0 maximum cancer density 10
6 cells/ml [16]
ζr the measure of efficacy of reverse transcriptase in-
hibitors(RTI)
[0, 1]
ζp the measure of efficacy of protease inhibitors(PI) [0, 1]
PM1 , PM2 , PT4 , PT i4
, PT8 chemo-induced immune cell death rates 0.6 day
−1 [47, 48]
PC chemo-induced tumor cell death rate 0.9 day
−1 [47, 48]
dD chemo drug elimination rate 0.9 day
−1 [47, 48]
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3.2 Results with no chemotherapeutic drug
The results presented below of the numerical simulations for system (3) were obtained using
Matlab ODE45 Solver which employ simultaneously the fourth and fifth order Runge Kutta
schemes.
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(a) With no HIV treatment; ζp = ζr = 0 and β3 = 2.0 ×
10−5 − 5.5× 10−5 steps of 2.5× 10−6
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(b) With HIV treatment; ζp = ζr = 0.8 and β3 = 2.0 ×
10−5 − 5.5× 10−5 steps of 2.5× 10−6
Figure 2: The g(C) as a function of C with different values of β3 (rate of cancer loss in the
population) with other parameters as in Table 2 and the other variables at their steady states.
No chemotherapy treatment initiated.
Figure (2) shows the results of our simulation for g(C) as a function of C, with different values
of tumor killing rate, β3. Every one of the trajectories represents different parameter value of
β3 and the values increase from top to the bottom line. The values considered were in the
range 2 × 10−5 to 5.5 × 10−5 for both cases; with and without HIV treatment with a step size
of 2.5 × 10−6 (arithmetic distribution). A closer look at the trajectories, interestingly show
that HIV treatment is important in cancer growth control. A typical example is to consider
β3 = 4.25× 10−5 represented by the thicker trajectories. Without treatment we can have three
possible cancer steady states while one steady state is observed for the case with treatment.
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(a) No HIV treatment, ζp = ζr = 0.0
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(b) With HIV treatment, ζp = ζr = 0.8
Figure 3: Bifurcation diagram: Non-trivial solutions of g(C∗) = 0 as a function of β3 with the
rest of parameters as in Table (2) with the other variables at their steady states.
From the analysis in Figure (2), we observe that the parameter β3 is important in our model
since it plays an effective role in defining the tumor behaviour. We thus investigate numerically,
the bifurcation of the model for parameter β3, responsible for the immune response. The graphs
in Figure (3), display the bifurcation diagrams for the treatment and no treatment cases. Figures
(3a) and (3b) are plots of the non-zero steady state solutions of g(C∗) = 0 as a function of the
parameter, β3. This analysis helps in understanding the behaviours of the model, i.e the critical
values of the bifurcation parameter where the behaviour of the model system (3) changes. Figure
3 shows two saddle node bifurcation points. We observe the existence of multiple equilibria with
respect to the different range of values for β3. Considering Figure 3a, one steady state exists for
both β3 < 3.27 × 10−5 and β3 > 4.43 × 10−5 (these exact values where the bifurcation occurs
are obtained from the plots in Figure 2a). However, for 3.27× 10−5 < β3 < 4.43× 10−5 we have
three equilibria. It is also clear from the figure that the upper branch where β3 < 4.43 × 10−5
and the lower branch of the graph where β3 > 3.27 × 10−5, we have stable equilibrium of
the tumor whereas for the middle is unstable equilibrium. The same is evident for Figure 3b
where one solution exists for both β3 < 2.91 × 10−5 and β3 > 3.945 × 10−5 and three for
2.91× 10−5 < β3 < 3.945× 10−5.This implies that for the regions β3 > 4.43× 10−5 in Figure 3a
and β3 > 3.945×10−5 in Figure 3b, all the trajectories are attracted to the trivial tumor solution
or the non-aggressive steady state disregarding the initial conditions. For β3 < 3.27 × 10−5 in
Figure 3a and β3 < 2.91 × 10−5 in Figure 3b, the aggressive tumor equilibrium is an attractor
for all the initial conditions.
A consideration of the same initial conditions, say (C, β3) = (1 × 105, 3.5−5), in Figures (3a)
and (3b) yields different long term dynamic results. In the absence of treatment, the system
will eventually settle to the aggressive steady state. On the hand, in the presence of treatment,
the system settles to a non-aggressive steady state. This underscores the importance of HIV
treatment and early identification of the cancer.
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The population dynamics of the tumor cell of our system is depicted in the time series plot,
Figure (4), where the solution is observed to stabilize after around 512 years for a value of
β3 = 1
−7.
0 500 1000 1500 2000
0
1
2
3
4
5
6
7
8
x 105
Time (days)
Ca
nc
er
 c
el
ls,
 C
Figure 4: Population dynamics of the tumor cells in model system (3) with the parameters as
in Table (2). Initial conditions: M1(0) = 2000 cells/ml, M2(0) = 2500 cells/ml, T4(0) = 5× 105
cells/ml, T i4(0) = 0 cells/ml, V (0) = 1000 copies/mL, T8(0) = 100cells/ml and C(0) = 100
cells/ml.
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(a) µ2 = 2.4× 10−8
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(b) µ2 = 2.4× 10−5
Figure 5: Population dynamics of the tumor cells in model system (3) with only HAART
therapy, with ζr = ζp = 0.5 and the rest of the parameters as in Table (2). Initial conditions:
M1(0) = 2000 cells/ml, M2(0) = 2500 cells/ml, T4(0) = 5 × 105 cells/ml, T i4(0) = 0 cells/ml,
V (0) = 1000 copies/mL, T8(0) = 100cells/ml and C(0) = 100 cells/ml.
The time series plot in Figure (4) is considered for different infection rates, µ2 = 2.4× 10−8 and
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µ2 = 2.4 × 10−5 in the presence of HIV treatment. The results are presented in Figure 5. As
seen in Figures 5a and 5b, for a smaller infection rate, treatment reduces tumor growth while
treatment has no effect on the tumor growth for high infection rate values. So, treatment alone
in the absence of reduced infection rates does not have a significant impact on cancer growth
dynamics.
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(a) µ2 = 2.4× 10−8
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(b) µ2 = 2.4× 10−5
Figure 6: Numerical simulation of model system (3) for the evolution of the CD8+ T cells
(effector cells) with RTIs and PIs treatment of efficacies, ζr = ζp = 0.5 and the rest of the
parameters as in Table (2). Initial conditions: M1(0) = 2000 cells/ml, M2(0) = 2500 cells/ml,
T4(0) = 5 × 105 cells/ml, T i4(0) = 0 cells/ml, V (0) = 1000 copies/mL, T8(0) = 100cells/ml and
C(0) = 100 cells/ml.
Figure (6) shows the dynamics of the CD8 T cell population. For Figure 6(a), where the infection
rate of the CD4+ T cells is low, we observe significant growth of the CD8 T cells in the presence
of treatment. Similarly, as in Figure 5b, no changes are obtained for higher infection rates.
3.3 Results with chemotherapeutic drug
Considering the parameter associated with chemotherapy intervention, uin(t), we assume admin-
istration of 2.3869 mg/L ' 2386900 pg/mL per every 21 days for tumors, as suggested in [48].
Therefore, if T (every 21 days) is the drug infusion time, then the mass inflow is given by
uin =
{
2.3869, t = T = 21n, n = 1, 2, ...
0, otherwise
With the inclusion of chemotherapy in the model, no difference is seen for the cases with and
without HAART therapy. Chemotherapy administration occurs when the tumor is large and
detectable, thus considering the initial state of tumor as 1 × 105cells/ml, we observe that the
drug is very effective in eliminating the tumors when the decay rate in the system is smaller.
Administering same therapy but with a higher decay rate in the system, the tumor will not be
eliminated and instead the tumors will regrow as seen in Figure 7a. This implies that the length
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(a) Drug elimination rate, dD = 0.9 with a log scale on
the vertical axis.
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Figure 7: Population dynamics for a period of 200 days of the tumor cells in model system
(3) with both therapies (HAART and chemotherapy) with parameters as in Table (2). Initial
conditions: M1(0) = 2000 cells/ml, M2(0) = 2500 cells/ml, T4(0) = 3 × 105 cells/ml, T i4(0) =
1× 103 cells/ml, V (0) = 4× 103 copies/mL, T8(0) = 3000 cells/ml .
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Figure 8: Chemotherapeutic drug dose concentration in the system administered 1 day every 21
days for 200 days i.e 9 doses every 21 days.
of time a chemotherapeutic drug has to act against the tumor is very critical since smaller decay
rate/ elimination rate implies a longer time required to act against the tumor. Figure 7b thus
shows the effect of smaller decay rate on tumor elimination.
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4 Discussion and Conclusions
In this paper we investigated the role of HIV in the model of AIDS-related non-Hodgkin Lym-
phoma by considering cytokines, macrophages, CD4+ T helper cells, CD8+ T effector cells and
the virus in the tumor environment.
From the analysis, it suffices to deduce that when HIV is present in the tumor environment and
no treatment of the HIV initiated in the patient, for a non-aggressive tumor state to be achieved
the tumor killing rate has to be higher , i.e. higher immune response as compared to the case
where treatment of HIV with HAART is initiated. This implies that the timing of initiating
HIV treatment in patients with the tumor is an important factor since the tumor can remain
in a non-aggressive state despite lower immune response (the comparison is done with respect
to no treatment case). The bifurcation analysis shows that treatment plays an important role
in shifting the steady states. We notice that given the same value of parameter β3, the steady
states values decrease when HIV treatment is included in the model system and for most of the
parameter value β3, the existence of only low endemic tumor state is observed. This implies that,
as opposed to the no HIV treatment scenario, the tumor can be controlled to a non-aggressive
state despite low immune response.
We also observe that when the HIV infection rate is low, initiating treatment in patients with
HIV-related NHLs reduces tumor growth. Also, no effective control of the tumor will be observed
despite HIV treament as long as the tumor killing rate is small, i.e. weak immune response. Our
model represents a possible long-lasting coexistence of HIV-related NHLs and HIV, because
of the existence of the non-zero equilibria. Despite a patient’s strong immune response and
treatment of the HIV with the reverse transcriptase inhibitors (RTIs) and protease inhibitors
(PIs) drugs of efficacy for instance, 50% in our case, complete elimination of the tumor by the
immune system is actually not possible. The tumors will still remain in the host system unless
the tumor elimination rate is very high, though at a lower state that is not so destructive and
thus the patient survives with the tumors for a longer period of time. This could also explain why
some people live with cancer for many years. Moreover, it can also explain why late initiattion
of HIV treatment is not very helpful to NHL patients. In the case of chemotherapy, the time
taken by the drug to act on the tumor is an important factor and thus to reduce cancer related
deaths, the chemotherapeutic drugs used should have low elimination rates. This implies that
the absorption, distribution and clearance of the drugs take much longer time and this might
explain why a few of these drugs are more effective when given at a slow continuous rate for a
few days at a time.
The model presented in this paper is a very simplified caricature of a complex biological interac-
tion of immune cells, cytokines and HIV in a tumor environment and therefore it has some lucid
limitations. The model does not take into account the spatial growth of the tumors and the
associated metabolic elements and pathways. We also restrict the NHL to some environment,
like the lymph nodes despite the fact that they can be found in many parts of the body. There
is also paucity of experimental data for model verification. Despite these limitations, the model
results have significant bearings on NHL dynamics and its coexistence with HIV.
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Abstract Highly active antiretroviral therapy (HAART) used for HIV treatment is a combination ther-
apy, that includes reverse transcriptase inhibitor (RTI) and protease inhibitor (PI) in different proportions;
it is more effective in treating HIV than a single drug therapy. HIV/AIDS associated cancers are cancers
whose incidence is much higher in HIV/AIDS patients than in the general population. In many commu-
nities in sub-Saharan Africa, HAART is available but not anti cancer drugs. In this paper we develop
a mathematical model to explore how effective is the combination therapy in HIV associated cancer in
reducing cancer growth. Our model simulations show how to choose the proportions of RTI and PI in
order to maintain an acceptable level of CD+4 T cells and, at the same time, reduce the growth of cancer
cells as much as possible. Although our model is generic, it could be used as a first step in developing a
more detailed model for a specific HIV-associated cancer.
Keywords HAART · HIV · HIV/AIDS · associated cancer · simulation
1 Introduction
The hallmark of Human immunodeficiency virus (HIV) is deficiency in CD4+ T cells, caused by the virus
which infects them and causes their destruction. The disease is characterised as acquired immunodefi-
ciency syndrome (AIDS) when the number of T cells falls from 700000 in ml of blood to 200000. The
most effective anti HIV drug is HAART, a combination drug of reverse transcriptase inhibitor (RTI) and
protease inhibitor (PI). Since CD4+ T cells are an important component of the immune defense against
diseases and in particular against cancer, people with advanced stage of HIV are at risk of developing
cancer.
The majority of cancers affecting HIV-positive people are Kaposi sarcoma (KS), non-Hodgkin’s Lym-
phoma (NHL) and invasive cervical cancer (Newcomb-Fernandez, 2003). Other types of cancer which occur
somewhat more frequently in HIV/AIDS patients include, anal cancer (Newcomb-Fernandez, 2003), lung
cancer (Mani et al., 2012; Newcomb-Fernandez, 2003), and colorectal cancer (Ford et al., 2008). KS is
an indolent cancer, involving multiple tumor of the lymph nodes or skin, and occuring mainly in people
with depressed immune system. Cervical cancer is caused by several types of virus, the most common one
is human papillomavirus (HPV). NHL is a blood disease which is characterised by abnormal growth of
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mutated lymphocytes (Hoffmann et al., 2015; Moosa, 2012; Stebbing et al., 2004). A positive correlation
between immunosuppression and increased incidence of Hodgkin disease (HD) has been demonstrated in
several studies, and those infected with HIV are 7.6 to 11.5 times more likely to have HD compared to
the general population (Newcomb-Fernandez, 2003).
Cancer is treated by surgery, radiation, immunotherapy and chemotherapy. An individual with HIV
who develops cancer, should be treated for both cancer and HIV. However, in poor communities around
the world where anti HIV drugs are nevertheless available, anti cancer treatment is almost non-existent.
For example, the estimates regarding access to or coverage of the cytotoxic chemotherapy in sub-Saharan
Africa are largely unknown(Mwamba et al., 2012). The study by (Gopal et al., 2012) also indicates that,
out of the 54 sub-Saharan Africa countries, only 21 have operational radiotherapy service units. The delay
and misdiagnosis of lymphoma, more specifically the diffuse large B-cell NHL in HIV patients, remains
a major problem in South Africa (Puvaneswaran and Shoba, 2013): Cancer, especially NHL, is often
misdiagnosed as tuberculosis, and this implies that patients living with HIV and HIV-related NHL are
only introduced to HAART, instead of receiving the anti-cancer drugs.
We quantify the efficacy of RTI by a parameter ζr where 0 ≤ ζr ≤ 1 and say that the efficacy of RTI
is n% if ζr = n/100. Similarly we quantify the efficacy of PI by a parameter ζp, where 0 ≤ ζp ≤ 1. In view
of the inadequate supply of chemotherapeutic drugs and radiotherapy equipments as well as increased
incidences of NHL misdiagnosis and the lack of trained personnel in Sub-Saharan Africa (Gopal et al.,
2012; Mwamba et al., 2012; Puvaneswaran and Shoba, 2013), the question arises; Can RTI and PI be
combined in a way that will reduce the cancer load as much as possible, while maintaining acceptable
level of CD4+ T cells?
To answer this question we develop a mathematical model that describes the interactions of macrophages
(pro-inflammatory, M1 and anti-inflammatory, M2), T cells (healthy CD4
+ T cells, HIV-infected CD4+
T cells and CD8+ T cells), HIV, and cancer cells. The various cells interact with each other through
several cytokines.
Human tumor microenvironment includes macrophages and these tumor associated macrophages
(TAMs) are phenotypically classified as M1 and M2 (Gordon and Martinez, 2010; Heusinkveld and van der
Burg, 2011). The M1 macrophages are associated with acute inflammation and T-cell immunity, and are
characterized by the expression of high levels of pro-inflammatory cytokines. The M2 macrophages are
anti-inflammatory and are associated with the promotion of cancer growth (Gordon and Martinez, 2010;
Heusinkveld and van der Burg, 2011; Roda et al., 2012). TAMs can switch type between pro-inflammatory
M1 and anti-inflammatory M2 in the tumor environment (Heusinkveld and van der Burg, 2011). IL-6 has
been identified as a key cytokine for the B-cell NHLs’ growth and survival (Zhang et al., 2012). TGF-β
has an inhibitory factor in the regulatory network of AIDS-related lymphomagenesis (Buske et al., 1999;
Ruff et al., 2007), and an immunosuppressive role, mediated predominantly by its effects on T cells and
antigen-presenting cells (APCs) (Dong and Blobe, 2000). IL-6 and TGF-β induce polarization of M2 into
M1 macrophages and promote an immunosuppressive environment (Zhang et al., 2012) . One of the most
important features of M1 macrophages is the production of a T-cell stimulating cytokine IL-12 which
enhances natural killer cell activities by activation of CD8 effector T cells(Villinger and Ansari, 2010). M2
macrophages produce IL-10 which down regulates the activities of IL-12, and thus inhibits the activation
of T cells by IL-12 (Asadullah et al., 2003; Groux et al., 1998; Trinchieri, 1997). CD4+ T cells produce
cytokine IL-2 which induces growth, proliferation and activation of both CD4+ T cells and CD8+ T cells
. CD8+ T cells, also called cytotoxic T cells (CTL), are directly involved in killing cancer cells (Lai et al.,
2011).
The model we develop is not specific to any cancer, and as clinical data becomes available, for instance
in the case of NHL, some of the parameters could be made more precise. The present model aims to
establish the concept that combination drugs available only against HIV can be judiciously adjusted to
be useful against cancer. The model focuses on the role of T cells in killing the cancer cells, since in HIV
infected individuals, the reduced number of T cells exacerbates cancer growth.
2 Mathematical model
The mathematical model therefore includes the variables listed in Table 1. The mathematical model is
based on the network described in Figure 1.
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Variable Description Units
M1 density of pro-inflammatory tumor associated macrophages cells/ml
M2 density of anti-inflammatory tumor associated macrophages cells/ml
T4 density of healthy CD4+ T cells cells/ml
T i4 density of virus-infected CD4
+ T cells cells/ml
V density of extracellular HIV virus/ml
T8 density of CD8+ T cells cells/ml
C density of cancer cells cells/ml
Tβ concentration of transforming growth factor (TGF-β) pg/ml
I6 concentration of interleukin 6 (IL-6) pg/ml
I10 concentration of interleukin 10 (IL-10) pg/ml
I12 concentration of interleukin 12 (IL-12) pg/ml
I2 concentration of interleukin 2 (IL-2) pg/ml
Table 1: Variables and their units
Fig. 1: Schematic representation of interactions of cells and cytokines in HIV-NH Lymphoma. We have
macrophages M1,M2, T-cells (immune cells) T4, T
i
4, T8, cytokines (Tβ , I6, I10, I12, I2), the cancer cells, C
and HIV, V . The pool of viruses V , through infection, affects the movement of the CD4+ T cells into the
infected compartment T i4. We have used dotted lines with arrow heads to represent cytokine production,
and cell activation and with square head to represent inhibition. The bold lines with arrow head represent
induction, transition or activation, and with square head represents killing.
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2.1 Model equations
2.1.1 Equations of the cytokines.
dTβ
dt
= α1C − d1Tβ ,
dI6
dt
= α6C − d6I6,
dI10
dt
= α10M2 − d10I10,
dI12
dt
= α12M1 − d12I12,
dI2
dt
= α2T4 − d2I2.

(1)
Tβ and I6 are produced by cancer cells (Fassone et al., 2000; Louzoun et al., 2014; Ruff et al., 2007), I12
and I10 are produced primarily by M1 and M2 macrophages respectively (Louzoun et al., 2014; Takeuchia
et al., 2002; Trinchieri, 1997), and I2 is produced by T4 cells (Lai et al., 2011). The parameters αi represent
the production of the cytokines by the respective cells the parameters di represent cytokines decay.
2.1.2 Immune cell equations
The dynamics of macrophages are given by the following equations
dM1
dt
= s1 − k1M1 + νM2 − (λ1Tβ + λ2I6)M1, (2)
dM2
dt
= s2 + (λ1Tβ + λ2I6)M1 − k2M2 − νM2, (3)
Here s1 and s2 are source terms for M1 and M2 macrophages, ν represents the unbiased interchange be-
tween these two macrophage phenotypes, and (λ1Tβ+λ2I6) is the rate by which additional transformation
occurs from M1 to M2 (Louzoun et al., 2014).
The density of CD4+ T cells, T4 satisfies the equation
dT4
dt
= s3 + β1
I12M1
K10 + I10
+ β2
I2T4
K2 + I2
− µ1T4 − (1− ζr)µ2V T4, (4)
with source term s3 and apoptosis rate µ1. T4 is further activated (from naive T cells) by I12 while in
contact with M1, a process resisted by I10 (Asadullah et al., 2003; Groux et al., 1998; Louzoun et al.,
2014). The third term on the right-hand side of equation (4) is the proliferation enhanced by I2 (Lai
et al., 2011), and the fourth term is the natural death of T4 cells. The last term is depletion of T4 as a
result of invasion by external virus, a process which is reduced by RTI drug as represented by the factor
1 − ζr, where 0 ≤ ζr ≤ 1. The RTI works by blocking the reverse transcription of viral DNA and can
therefore effectively prevent the target cell from becoming productively infected by the free virus. It is
worth noting that the inhibition process by RTI occurs after the virus has been attached to the cell and
therefore the drug does not directly affect the infection rate, µ2 of the target cells.
The density of infected T4 cells, T
i
4 satisfies the equation
dT i4
dt
= (1− ζr)µ2V T4 − µ5T i4, (5)
where in µ5 we included both the natural death rate and the burst rate δ2 of infected T4 cells, hence
µ5 > δ2. We assume that without HIV drugs, upon burst of one infected T4 cell, N virions are released.
However, this number will be decreased by a factor 1 − ζp, (0 ≤ ζp ≤ 1) under treatment with PI drug.
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PI blocks the action of HIV protease by preventing it from cleaving the viral polyprotein into functional
sub units which ultimately prevents the production of mature viruses. Hence
dV
dt
= (1− ζp)Nδ2T i4 − µvV, (6)
where µv is the death, or degradation rate of extracellular virus.
T8 cells are activated by I12, a process inhibited by I10 (Asadullah et al., 2003; Groux et al., 1998;
Louzoun et al., 2014), and by I2 (Lai et al., 2011). Since HIV does not invade into T8 cells, we have the
following equation;
dT8
dt
= β3
I12
K10 + I10
+ β4
I2T8
K2 + I2
− µ4T8. (7)
As in (Louzoun et al., 2014), we assume that the density of cancer cells (for instance, NHL cells which
are mutated B cells) follows universal growth law and that the killing of cancer cells by T8 cells follows
mass-action law:
dC
dt
= rC
3
4
(
1−
(
C
C0
) 1
4
)
− µcCT8. (8)
The parameters in the model system described in equations (1) - (8) are all non-negative.
2.2 The simplified model
The dynamics of cytokines is on a much faster scale than the dynamics of cells. Hence, following (Louzoun
et al., 2014), we simplify the model (1) - (8) by taking the cytokines dynamics in the equation (1) to be
in steady state, so that
Tβ =
α1
d1
C, I6 =
α6
d6
C, I10 =
α10
d10
M2, I12 =
α12
d12
M1, I2 =
α2
d2
T4.
Substituting these cytokines into Eqs.(2) - (8) we obtain
dM1
dt
= s1 − k1M1 + νM2 − γcCM1,
dM2
dt
= s2 + γcCM1 − k2M2 − νM2,
dT4
dt
= s3 +
γ1M1M1
K10 + γ2M2
+ β2
γ3T4T4
K2 + γ3T4
− µ1T4 − (1− ζr)µ2V T4,
dT i4
dt
= (1− ζr)µ2V T4 − µ5T i4,
dV
dt
= (1− ζp)Nδ2T i4 − µvV,
dT8
dt
=
γ4M1
K10 + γ2M2
+ β4
γ3T4T8
K2 + γ3T4
− µ4T8,
dC
dt
= rC
3
4
(
1−
(
C
C0
) 1
4
)
− µcCT8,

(9)
where γc = λ1
α1
d1
+ λ2
α6
d6
, γ1 = β1
α12
d12
, γ2 =
α10
d10
, γ3 =
α2
d2
and γ4 = β3
α12
d12
.
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3 Parameter estimation
Table 2 provides the description and values of all the parameters that appear in Eqs.(1)-(8). Most of
the parameters are taken from the literature, although not always from cancer experimental data. The
parameters s3 and α1 are estimated as follows;
We assume that at steady state of HIV infected person, when he/she still appears to be normal,
T4 = 500000 cells/ml. Since µ1 = 0.02/day (V.C.Rebecca and Sigui, 2000), from the cancer-free steady
state equation s3 − µ1T4 = 0 and µ1 = 0.02/day we then get s3 = 10000 cells/ml day. In normal
healthy individual, the average monocyte content is 400000cells/ml (mon). We assume that monocytes
differentiate mostly into M1 macrophages as they move from the blood into the tissue, and thus take
M1 = 400000cells/ml. From the cancer-free steady state equation s1 − k1M1 = 0 and k1 = 0.02/day, we
get s1 = 8000 cells/ml/day. It is known that tumor attracts myeloid derived suppressor cells (MDSC),
cells that have similar behaviour to M2 cells(Sevko and Umansky, 2013). We identify MDSC with M2,
and for simplicity consider this source of macrophages as a source term s2. We assume that this source is
small in comparison to the source of M1 macrophages, and take s2 = s1/10 = 800cells/ml/day. Since k2 =
0.008/day, the steady state equation s2− k2M2 = 0 yields the steady state density M2 = 100000cells/ml.
We take the values of parameters λ1 and λ2 to be 0.075 day
−1 as in (Yunji et al., 2012). We also assume
that β4 = β2 and β3 = 0.5β1. We finally take N = 1000, although this number varies in different studies
(V.C.Rebecca and Sigui, 2000).
Table 2: Estimated Parameter values.
Parameter Description Values Units Source
α2 production rate of IL-2 due to CD4+ T cells 5 pg/cell day (Arciero et al., 2004; Kirschner and Panetta, 1998)
α1 production rate of TGF-β due to cancers cells 7× 10−4 pg/cell day (Arciero et al., 2004; Tzai et al., 1999)
α6 production rate of IL-6 due to cancers cells 7× 10−5 pg/cell day Estimated
α10 production rate of IL-10 due to M2 5× 10−4 pg/cell day (J.Day et al., 2008; J.P.Edwards et al., 2006; Yunji et al., 2012)
α12 production rate of IL-12 due to M1 3× 10−2 pg/cell day Estimated in(J.Day et al., 2008)
d1 degradation rate of TGF-β 10 day
−1 Estimated in (Arciero et al., 2004)
d2 degradation rate of IL-2 10 day
−1 (Kirschner and Panetta, 1998; Rosenberg and M.T.Lotze, 1986)
d6 degradation rate of IL-6 0.173 day
−1 (Lu et al., 1995)
d10 degradation rate of IL-10 5 day
−1 (J.Day et al., 2008)
d12 degradation rate of IL-12 1.188 day
−1 (J.Day et al., 2008; Ohno et al., 2000)
s1 influx rate of M1 8000 cells/ml day Estimated
s2 influx rate of M2 800 cells/ml day Estimated
s3 production of CD4+ T cells by the sources 10000 cells/ml day Estimated
k1 per capita death rate of M1 0.02 day
−1 (J.Day et al., 2008)
k2 per capita death rate of M2 8× 10−3 day−1 (J.Day et al., 2008; Keane et al., 1997)
λ1 transformation rate of M1 by TGF-β 0.075 day
−1 Estimated in (Yunji et al., 2012)
λ2 transformation rate of M2 by IL-6 0.075 day
−1 Estimated in (Yunji et al., 2012)
ν transition rate from M2 to M1 5× 10−2 day−1 (Steinmller et al., 2000; Yunji et al., 2012)
β1 proliferation rate of T4 cells due to IL-12 106 cells/ml day (Hao and Friedman, 2014)
β2 proliferation rate of T4 cells by IL-2 0.1245 pg/cell day (Arciero et al., 2004; Kirschner and Panetta, 1998; Kuznetsov et al., 1994)
β3 proliferation rate of T8 cells due to IL-12 0.5× 106 cells/ml day assumed
β4 proliferation rate of T8 cells by IL-2 0.1245 pg/cell day assumed
µc loss of cancer cells 10−5 ∼ 10−9 day−1 (Louzoun et al., 2014; Seki et al.; Wilson and Levy, 2012) and estimated (10−9)∗
K2 saturation constant of proliferation by IL-2 2× 107 pg/ml (Kirschner and Panetta, 1998; Kuznetsov et al., 1994)
K10 saturation constant for anti-proliferation by IL-10 2.5× 107 pg/ml (Hao and Friedman, 2014)
µ1 per capita death rate of uninfected CD4+ T cells 0.02 day
−1 Estimated in (V.C.Rebecca and Sigui, 2000)
µ2 infection rate of CD4+ T cells due to infiltration by free viruses 2.4× 10−8 ml/day Estimated in (V.C.Rebecca and Sigui, 2000)
µ4 per capita death rate of CD8+ T cells 0.03 ∼ 0.0412 day−1 (Kirschner and Panetta, 1998; Kuznetsov et al., 1994)0.03∗
µv clearance rate (loss) of free viruses 2.4 day
−1 Estimated in (V.C.Rebecca and Sigui, 2000)
µ5 per capita death rate of infected CD4+ T cells 0.26 day
−1 Estimated in (V.C.Rebecca and Sigui, 2000)
δ2 lytic death rate of infected CD4+ T cells 0.24 day
−1 Estimated in (V.C.Rebecca and Sigui, 2000)
N Virions produced during a lifetime by an infected CD4+ T cells Varies Estimated in (V.C.Rebecca and Sigui, 2000)
r cancer growth rate 0.18 ∼ 0.19 day−1 (Arciero et al., 2004; Kirschner and Panetta, 1998; Kuznetsov et al., 1994; Wilson and Levy, 2012) 0.19∗
C0 maximum cancer density 106 cells/ml Estimated in (Louzoun et al., 2014)
N number of virions released upon burst by an infected T4 cell 1000 cells/ml (V.C.Rebecca and Sigui, 2000) and assumed
ζr the measure of efficacy of reverse transcriptase inhibitors(RTIs) [0, 1]
ζp the measure of efficacy of protease inhibitors(PIs) [0, 1]
* value chosen in the simulation.
4 Simulation results
The results presented below of the numerical simulations for system (9) were obtained using Matlab
ODE45 Solver which employs simultaneously the fourth and fifth order Runge Kutta schemes. Unless
otherwise stated, parameters are as stated in Table 2.
We take the following initial conditions: M1(0) = 400000 cells/ml, M2(0) = 100000 cells/ml, T4(0) =
500000 cells/ml, T i4(0) = 0 cells/ml, V (0) = 1000 copies/ml, T8(0) = 100 and C(0) = 100 cells/ml.
We explore the effect of combined HIV therapy on the cancer. Recall that one type of drugs (RTIs)
reduces the infection of T4 cells by virus by a factor 1− ζr, while another type of drugs (PIs) reduces the
proliferation rate of virus within infected T4 cells by a factor 1 − ζp. As mentioned in the introduction,
we shall say that RTI has efficacy of n% if ζr = n/100, and similarly PI has efficacy of n% if ζp = n/100.
Figure 2 is a combination therapy map for cancer cells. Starting with C(0) = 100 cells/ml, it shows
the density of cancer cells at days 350, 1000 and 20000 for any combination of ζr and ζp. In particular,
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(a) Contour plot showing cancer cells density after 350 days
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(b) Contour plot showing cancer cells density after 1000 days
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(c) Contour plot showing cancer cells density after 2000 days
Fig. 2: Combination therapy map: C(t), for t=350, 1000 and 2000 days as a function of RTI (ζr) and PI
(ζp) combination, the parameters are as in Table 2. The color bar shows the C(t) values for various drug
combination.
with no drugs, C(350) = 5.25 × 104 cells/ml, C(1000) = 4.3 × 105 and C(2000) = 8.54 × 105. From the
convex shape of the equi-cancer-cell-number curves we see that if two drugs, ζr with efficacy n% and ζp
with efficacy m%, (n+m < 100) can be replaced by just one drug, say ζr, with efficacy ζr = (n+m)%
then the result will lead to a decrease in the growth of the cancer.
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(a) Contour plot showing CD4 T cells density after 350 days
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(b) Contour plot showing CD4 T cells density after 1000 days
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(c) Contour plot showing CD4 T cells density after 2000 days
Fig. 3: Combination therapy map: T4(t), for t=350, 1000 and 2000 days as a function of RTI (ζr) and
PI (ζp) combination, the parameters are as in Table 2. The color bar shows the T4(t) values for various
drug combination.
Figure 3 is a color map of T cells at t=350, 100 and 2000 days as a function of ζr and ζp. Similar
to Figure 2, we see that if the two drugs with efficacies m% and n% can be replaced by one drug with
efficacy (n+m < 100) then the resulting number of CD4+ T cells will increase.
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5 Discussion and conclusions
In this paper we investigated the effect of HIV treatment on AIDS-related cancers (including for example
NHL). We developed a mathematical model which includes; macrophages, CD4+ T helper cells and
CD8+ T effector cells, various cytokines produced by these cells and by cancer cells, and the virus.
We investigated the effect of combined RTI and PI drugs on reduction of cancer load. We created a
combination therapy map for cancer-cells number, C(t), for t=350, 1000 and 2000 days as a function of
ζr and ζp combination. The results show how to best choose a combination of the two drugs that reduces
the cancer load in the host environment while maintaining the CD4+ T cells at an ’acceptable’ level.
Indeed, suppose we wish to maintain the CD4+ T cells population at level T 4 = 500000cells/ml after
1000 days. We use Figure 4 to determine the pairs ζr, ζp for which the corresponding equi-color curve
indicates the level T 4; we can write these pair of points as ζp = h(ζr) where h is a monotone decreasing
function. Next, for each pair ζr, h(ζr) we depict from Figure 3 the corresponding value of C(1000), and
denote it by C(ζr). As we vary ζr over the range of all possible efficacy levels, say a < ζr < b, for which
ζr = h(ζr) is also a realizable efficacy level, we obtain a range of values C(ζr). Figure 4 shows a typical
curve C = C(ζr); we see that the smallest number of cancer cells occurs at one of the extreme points, i.e
at ζr = a or ζr = b. Thus, the best strategy is to choose the minimum or maximum level of efficacy for
ζr and the corresponding ζp by ζp = h(ζr).
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Fig. 4: Cancer cell density curve, C(ζr) at t = 1000 days, for each pair (ζr, h(ζr)), the parameters are as
in Table 2.
We developed a mathematical model of HIV-associated cancer, and determined how to optimally
choose the proportions of RTI and PI in the anti HIV combination drug HAART in order to maintain an
acceptable level of CD4+ T cells and, at the same time, to reduce cancer growth as much as possible. The
model however is generic; it is not cancer specific. Building on this model, future work should consider
specific cancers, for example NHL, and by expanding the model to include additional relevant cells
and cytokines, and more precise clinically or experimentally derived parameters, provide an improved
prediction of the optimal combination of RTI and PI.
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